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This thesis consists of the combination of two projects: 
The first project investigated the enzyme NfsB from Eschericia coli (a bacterial 
Nitroreductase), which has now entered the clinical trial stage with the pro-drug [5-(aziridin-
1-yl)-2,4-dinitrobenzamide] (CB1954) as the enzyme reduces this inert pro-drug into its toxic 
hydroxylamine derivative.  
The second project investigated the Platelet derived growth factor tyrosine kinase receptor 
PDGF β, which investigated the current hypothesis that Protein Kinase C (PKC) is a point of 
signal integration for PDGF receptor recycling. 
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First Thesis 
 
Abstract  
 
The enzyme NfsB from Eschericia coli is a bacterial Nitroreductase, which has now entered 
the clinical trial stage with the pro-drug [5-(aziridin-1-yl)-2,4-dinitrobenzamide] (CB1954) as 
the enzyme reduces this inert pro-drug into its toxic hydroxylamine derivative. In this study 
the poly histidine tag which was added onto the wild type NfsB (to allow affinity 
purification) was investigated and it was determined that it had a negative effect on the 
specificity constant (kcat/Km) of wild type NfsB for CB1954, reducing to half the original 
value, however a statistical significance was not observed. In addition once the histidine tag 
was cleaved, the original level of activity did not return as the recombinant enterokinase did 
not cleave the entire tag and a statistical significance was observed for the rate of menadione 
reduction when comparing to WT NfsB. Furthermore the activity of wild type NfsB and the 
unnatural amino acid mutant napthylalanine with menadione were also determined, 
concluding that menadione is a far better substrate for both the wild type and napthylalanine 
NfsB mutant, improving the specificity constant by 40/50 times. Nevertheless, the 
napthylalanine NfsB mutant showed a statistically significant lower activity with the pro-drug 
in comparison to the wild type NfsB, which was due to the low concentration and impurity of 
the sample obtained for napthylalanine NfsB. Finally a crystal of the cleaved wild type NfsB 
was grown, however this was twinned and the diffraction pattern could not be solved.  
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1. Introduction 
 
1.1Background 
 
On average 12.7 million individuals are diagnosed with cancer annually around the globe, 
with 267 cases for every 100,000 individuals within the U.K making it the 22nd highest 
cancer rate in the world (WCRFI, 2011). This disease has been identified and acknowledged 
as a disorder with high morbidity and mortality rates; therefore highlighting the great need for 
developing therapeutic solutions (WCRFI, 2011). Malignant neoplasm, commonly referred to 
as cancer, is a term used to cover a vast number of different cancerous types. Generally the 
cells in cancer patients replicate uncontrollably and result in the formation of tumours. These 
can be classified as either benign or malignant tumours; in the benign form the tumour 
doesn’t spread and remains localized (Davis and Balentine, 2012). However in malignant 
tumours, the cancer cells are undergoing rapid replication, infiltrating and spreading into 
other and distant parts of the body, through the lymphatic system and bloodstream (Davis and 
Balentine, 2012). These malignant transformations occur as oncogenes are over expressed 
through the inhibition, destruction or mutation of the tumour suppresser genes, resulting in 
uncontrollable replication of both normal and abnormal cells. Generally, a number of genes 
are required to transform within the normal cells in order to produce a cancerous cell (Davis 
and Balentine, 2012). Nevertheless, the mortality of cancer has reached significant figures, 
with an average of 7.6 million deaths reported in 2008 (WHO, 2008) 
Chemotherapy is one of the major treatments of cancer, which holds an important position in 
the struggle against this disease; however there are several limitations, which result in the 
failure of such methods. It involves the use of antineoplastic drugs in order to treat cancer; 
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these drugs target rapidly dividing cells which consequently affect the bone marrow, 
digestive tract and hair follicles (Goldwein and Vachani, 2010). These types of drugs include 
DNA alkylating agents, which damage the DNA and nucleotide analogues functioning as 
anti-metabolites and preventing DNA replication. The main issues surrounding this treatment 
includes the deficiency in drug delivery to the tumour site, toxicity caused and most 
significantly the insufficiency of selectivity for tumour cells causing high system toxicity (Xu 
and McLeod, 2001). The success of a therapeutic cancer treatment is generally defined by the 
percentage of drug delivery to the tumours in addition to limiting system toxicity (Wu & 
Chang, 2010). The majority of chemotherapeutic drugs aren’t specific to tumour cells and do 
not accumulate at these sites, with only a small percentage of the dosage delivered to the 
tumour, and approximately 75-90% of the dose accumulating in other organs (Ropert, 1999). 
As well as system toxicity, multidrug resistance has been one of the major causes for the lack 
of success in chemotherapy (Kowalski et al., 2002). There have been a vast number of 
approaches in order to address these setbacks, one of which is recruiting liposomes as a gene 
delivery system (Ropert, 1999; Wu and Chang, 2010; Krishna and Mayer, 1997).  This 
approach targets tumour associated endothelial cell receptors (on the cell surface) via 
encapsulating the chemotherapeutic drugs with liposomes that bind these receptors (Wu and 
Chang, 2010; Suzuki et al., 2007).  
The developments for methods addressing multidrug resistance in particular, are important as 
it is a significant obstacle; occurring as the tumour cells exposed to 1 type of 
chemotherapeutic drug, develop a form of resistance to that specific cytotoxic agent in 
addition to a range of other drugs which can differ in both structure and function (Thomas 
and Coley, 2003). This is caused by an increased expression of specific proteins, which affect 
the cell membrane (e.g. related membrane transporters) and cause an increase efflux of the 
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cytotoxic drug; decreasing intracellular concentrations (Thomas and Coley, 2003). However 
in some cases resistance has developed in the absence of previous drug administration. 
Since the establishment of gene therapy in 1990, new treatments became available via gene 
therapy combined with other therapeutic agents/methods which improved chemotherapy 
delivery (Davidoff, 2007; Suzuki et al., 2007). Gene therapy was initially established from 
the theory that disorders caused by a gene defect can be cured by the replacement or 
modification of the affected genes, therefore enabling the host cells to reverse the disease 
phenotype (via the transgene expression). Cancer in particular is ideal for this form of 
treatment due to its genetic foundation and potential for cellular exploitation. This includes 
targeting fundamental processes such as different phases of the cell cycle (Goldwein and 
Vachani, 2010).  These type of drugs can be cell cycle non specific, allowing it to destroy a 
cell during any phase. However other chemotherapeutic agents can also be cell cycle specific, 
only able to initiate cell destruction during specific phases. Generally during chemotherapy 
treatment, these drugs are combined in order for the two to complement one another 
(Goldwein & Vachani, 2010). 
 Although chemotherapy was established beforehand; the use of gene therapy has been 
exploited and adapted significantly since its breakthrough in 1990 (base for gene directed 
enzyme pro-drug therapy) (Prosser, 2011). This led to many therapeutic advances towards the 
treatment of cancer by combining cancer drugs with anti-tumour genes and resulting in gene 
directed enzyme pro-drug therapy (GDEPT) (Kowalski et al, 2002). This has proved to be an 
appealing area for local cancer treatment and tumour selectivity (Mitchel & Minchin, 2008). 
Treatment involves two main phases; initially the enzyme which will activate the biologically 
inert pro-drug, converting it into a potent toxic metabolite, must be expressed in the tumour. 
Therefore upon the administration of the non toxic pro-drug, it (the pro-drug) can be 
20 
 
converted into an active anticancer drug (Xu and McLeod, 2001). Although the pro-drug 
distribution within the body is extensive, the cytotoxicity caused will be limited to the cells 
expressing the transgene. This enables the use of higher concentrations of chemotherapy 
drugs, consequently improving the therapeutic index (Both, 2009). 
Furthermore, there are many vectors used for the delivery of the transgene in the target cell, 
however 2/3 of ongoing gene therapy have employed the use of viral vectors (figure1.1.1) 
(Herod, 2010). This is further categorized into 6 main virus vectors, with adenovirus vectors 
favoured for the delivery and packaging of the nitroreductase transgene (Herod, 2010). This 
is delivered either locally into the tumour or systemically, which will then express the 
transgene (in tumour cells that have taken up the vector) and produce the corresponding 
protein.  This will then convert the administered pro-drug into its toxic metabolite as well as 
transfecting neighbouring cells, also referred to as the bystander effect (figure 1.1.2) (Prosser, 
2011). 
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Figure 1.1.1:  Vectors used in gene therapy clinical trials (Herod, 2010). 
The most common vector is a viral one which encapsulates the transgene, delivering the 
genetic material through transduction. The favoured viral vector for the delivery of the 
nitroreductase transgene in molecular chemotherapy is the adenovirus vector, which is one of 
the most common viral vectors used. It is a non-enveloped icosohedral virus, which can hold 
great sections of the DNA, in addition to being able to rapidly infect a vast variety of human 
cell (Genomics, 2011).  
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Figure 1.1.2: Schematic Diagram of gene directed enzyme pro-drug therapy via the use of a 
viral delivery vector system to administer the enzyme gene (Prosser, 2011). 
The transgene is packaged and delivered either directly or systemically into the tumour. This 
then transcribes the transgene and translates the enzyme/protein. The inert pro-drug is 
administered intravenously and the enzyme/protein translated converts it (the pro-drug) into 
its toxic metabolite. This then damages the cell, killing it as well as transfecting neighbouring 
cells and causing the same result (bystander effect) (Prosser, 2011). 
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The nitro-aromatic pro-drug 5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) is a 
monofunctional alkylating agent with low toxicity, which had proved itself significant as an 
antitumour drug, against the rat Walker 256 carcinoma (Cobb et al, 1969). The pro-drug was 
initially discovered during the investigation of N-substituted-aziridine compound effects on 
the cancer model system; rat Walker-256 carcinoma. The CB1954 antitumour pro-drug had 
completely regressed and cured this carcinoma (Cobb et al, 1969). Further studies identified 
that the CB1954 pro-drug was enzymatically activated and its 4 nitro group (4-NO2) reduced 
to a 4-hydroxyl amine derivative (5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide: 4-
NHOH) (Friedlos et al.,1992). This reduction was catalysed by NAD(P)H: Quinone 
oxidoreductase 1 (NQO1), an oxygen insensitive reductase (Knox et al. ,2000 ; Prosser, 
2011).  
This reduction causes the compound to undergo both structural and electronic alterations 
within the aromatic ring; the alteration of electrons increases the hydrophilic ability of the 
ring and consequently increases DNA binding properties (Prosser, 2011). Alternative studies 
proposed that a non enzymatic interaction occurs between the 4-hydroxylamine and 
intracellular thioesters (specifically the acetyl-CoA) forming an N-acetoxy derivative. This is 
an extremely toxic compound which results in the formation of DNA-DNA inter-strand cross 
links within the cancer cells. The inability to repair this damage to the DNA correctly causes 
cell death (figure 1.1.3) (Christofferson, 2009; Prosser, 2011) 
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Figure 1.1.3: The Bioactivation of CB1954 (Prosser, 2011). 
The initial step is the enzymatic nitroreduction of the pro-drug, into either 2-hydroxylamine 
(2NHOH) or 4-hydroxylamine (4NHOH). Depending on which of the two the parental pro-
drug is reduced to, different products will be formed. In the case of 2NHOH, it is unstable 
and disproportionate in aqueous solutions. This produces nitroso derivates (compounds with 
functional group as RNO), not shown, and amine derivates (compound 3). Although it is 
unstable it has good bystander effects. In the case of the parental pro-drug reduction to 
4NHOH, it undergoes a further reduction to compound 6, a non toxic amine. However 
4NHOH can also react with the intracellular thioesters (specifically the acetyl-CoA) forming 
an N-acetoxy derivative, compound 5. Finally an increased acetylation of compound 5 can 
25 
 
result in the formation of compound 6, with only compounds 3 and 5 being able to form intra 
and inter strands cross-links with DNA forming monoadducts. (Prosser, 2011). 
This enzyme (NQO1) is also present in human cells, however due to a difference at residue 
104 (tyrosine to glutamine) the metabolism of the CB1954 pro-drug by the human NQO1 is 
significantly inferior (Xu and McLeod, 2001). Kinetic analysis comparing the enzyme 
activity of the human and rat form of this enzyme, showed them both to have comparable 
activity. However the human NQO1 enzyme was significantly lower in the activation of 
CB1954, with a kcat of 0.64/min; in comparison to the rat NQO1 enzyme, with an enzyme 
activity of Kcat of 4.1/min (Green et al., 2004).  However subsequent studies have shown the 
nitroreductase encoded by the NfsB gene of E. coli, enhances the efficiency of this 
bioreduction by nearly a 100 fold in comparison to the NQO1 enzyme in rats (Green et al., 
2004). This drug is excellent for the use in GDEPT, as the administration of CB1954 is non 
toxic at therapeutic levels, as well as the inability of normal human enzymes to activate this 
pro-drug to toxic levels (human NQO1 is a poor analogue) (Xu and McLeod, 2001). In 
addition, CB1954 is not cell cycle specific and thus can kill the cells independently of the cell 
cycle (Christofferson, 2009). 
The nitroreductase NfsB found in E. coli is part of the superfamily enzymes; bacterial 
nitroreductases, which are diverse and also found in prokaryotes (Prosser, 2011). These 
flavoproteins were initially discovered in 1940, for their effect on the antibiotic 
chloramphenicol, where they reduced the nitro group (Merkel and Steer, 1953). The NfsB 
NTR is made up of two subunit dimers; each containing 217 amino acids, and a FMN 
cofactor at its active site (Christofferson, 2009). Nitroreductases are a group of flavoproteins 
which have been found to reduce a diverse range of nitroaromatic compounds either 
aerobically (oxygen sensitive class I) or anaerobically (oxygen insensitive class II) (Koder et 
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al.,2002). This is through either 1 or 2 electron reduction steps with class I nitroreductases 
employing only one step and class two employing a single, simultaneous 2 electron transfer  
step (figure 1.1.4) (Koder et al.,2002; Prosser,2011).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
 
Figure 1.1.4: Schematic overview of the electron steps reduction of nitroaromatic compound 
(Prosser, 2011). 
Upon the reduction (1e-) of the initial nitroaromatic, an unstable nitro-anion radical is formed, 
which can be reversed to the parental nitroaromatic (through reacting with O2 – class I). In a 
further reduction of 1e- (either in absence in O2, with class 1 or – class II) the nitro group is 
converted, in an irreversible reaction to a nitroso metabolite and upon the reduction of a 
further 2e- the hydroxylamine derivative is produced. Finally a further reduction of 2e- the 
amino reaction product is produced (Koder et al., 2002; Prosser, 2011) 
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There have been three oxygen insensitive nitroreductase proteins identified in E. coli: NfsA 
(the major nitroreductase), NfsB and NfsC with minor nitroreductase activities. In 
comparison to NfsC, the other two proteins have been studied in a greater depth and 
identified to have similar enzymatic properties. NfsA and NfsB both employ 
flavomononucleotide (FMN) as a prosthetic group and use this to reduce the nitrocompounds 
via the Ping Pong Bi Bi mechanism. These NTRs use NAD(P)H as the reducing agent via a 2 
electron step reduction (figure 1.1 IV).  In the first step of the reaction FMN (Enzyme.FMN) 
is reduced via NAD(P)H and NAD(P)+ is released with the formation of E.FMNH2. In the 
second step of the reaction, different quinones and nitroaromatic substrates are 
reduced.(figure 1.1.5) (Anlezark et al, 2002; Lovering et al, 2001). The substrates (aromatic 
compounds/quinones) bind the active site of the reduced enzyme (Lovering et al, 2001). 
Figure 1.1.5: Schematic overview of the Ping Pong Bi Bi mechanism reduction of 
nitrocompounds (Anlezark et al, 2002; Lovering et al, 2001). 
Furthermore, although the wild type NfsB enhances the bio-reduction of CB1954 by nearly a 
100 fold; the affinity of the NTR for the pro-dug is still considerably low, as it is not a natural 
substrate (Christofferson, 2009). The result in a low percentage yield of pro-drug, activated 
into its toxic metabolite. The investigation of the exact mechanism is important as this can 
help determine vital amino acids at the active site, in order to mutate them and increase pro-
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drug activation (Christofferson, 2009). Therefore the 9 residues at the active site of the 
nitroreductase and surrounding the FMN co-factor were selected for site directed mutagenesis 
with a single mutation. These include ; Phe124, Ser40, Tyr68, Phe70, Asn71, Gly120, 
Glu165, Gly166, Thr41, from which the potential amino acid substitution were made and 
subsequently cloned into an E.coli bacteria (Grove et al, 2003). These showed a significant 
enhancement in the sensitization of the cells to the pro-drug enhanced sensitisation to 
CB1954 in an E. coli cell-killing assay; the decrease in bacterial was growth monitored (E. 
coli cell killing assay), implying the improved activity of the pro-drug. The most active single 
mutants were found at the Phe124 site, which had 15 amino acids replaced, resulting in an 
increased drug activity (Grove et al, 2003). It has been proposed that this is due to the 
hydrophobic side chain, partially restricting binding of the substrate (Grove et al, 2003).  
Other improvements were also at the Ser40 site, by mutating it to residues which have small 
side chains (e.g. alanine/glycine). In constrast Thr41 only showed improvements with long 
hydrophobic, glycine or polar groups. Tyr68 also improved with glycine and in addition 
asparagines (Grove et al, 2003). Phe70, however, is located near the opening of the active 
site, which resulted in several residues that caused an improvement. This is most likely due to 
its location, and that it allowed an increased admission to the active site in addition to 
reducing product release. Finally Asn71 only produced an improvement with a polar residue 
(e.g. Serine) (Grove et al, 2003).   
The Phe124 site had emerged as an important factor in the binding of the substrate and thus 
different single unnatural amino acids were incorporated at the phe124 site (Jackson et al, 
2006).  These all had different effects on the activation of CB1954, however F124 & F124N 
were revealed to be the most significant as they increased the cell sensitivity to the pro-drug 
by five times (Jackson et al, 2006). Studies have suggested that this is due to the Phe12 pi 
stacking with the aryl ring of either the CB1954 or NAD(P)H as a response to the occupation 
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of the active site. Therefore it is considered that the Phe124 interacts with the substrate bound 
to the cofactor, and as the active site becomes occupied, it also interacts with the opposite 
subunit (Jackson et al, 2006). 
This has led to the incorporation of unnatural amino acids into the active site, which further 
enhanced the activity of the pro-drug over the most successful natural amino acid  (figures 
1.1.6/7) (Jackson et al, 2006). 
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Generation 1: p-aminophenylalanine (pAF), naphthylalanine (Nap), p-benzoylphenylalanine (pBpa), p-methyoxyphenylalanine (pMOF).  
Generation 2: p-aminomethylphenylalanine (pAMF), pmethylphenylalanine (pMP), p-trifluoromethylphenylalanine (ptfmF), p-
nitrophenylalanine (pNF) (Jackson et al, 2006). 
 
Figure 1.1.7: CB1954 kcat/Km with the different 
natural and unnatural modifications at site 124.  
This figure illustrates the improvement of CB1954 
activation by incorporating unnatural amino acids 
(Jackson et al, 2006).  
Figure 1.1.6: Nitroreductase 
modifications; natural and unnatural 
amino acids incorporated at site 124 
(Jackson et al, 2006). 
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This project investigated the wild type NfsB protein and the single unnatural amino acid 
mutant Napthylalanine at position 124, and comparing the rate at which these can reduce 
the CB1954 pro-drug as the aforementioned studies have shown it to have a higher 
specificity constant for the pro-drug, in comparison to wild type NfsB (Jackson et al, 2006; 
Grove et al, 2003). However the wild type NfsB used in this project was expressed with 
the addition of a poly-histidine tag, to allow for affinity purification on a nickel NTA 
column. Therefore the initial objective was to investigate whether the poly-histidine tag 
had an effect on the enzyme’s capabilities of substrate reduction. Furthermore, the steady 
state kinetics of the wild type NfsB were assessed and compared with those of the 
unnatural amino acid mutant Napthylalanine at position 124. In addition although the 
unnatural amino acid Napthylalanine NfsB at position 124 increases the specificity of the 
protein for the pro-drug, there are still a vast number of combinations of potential residue 
mutations. This makes it nearly impossible to improve the NTR any further, without 
specific knowledge of the substrate binding to the active site and the general reaction 
mechanism. Therefore the second part of the project investigated the enzymes reduction of 
another substrate: menadione. This is important as the binding orientation of different 
substrates and their reduction by FMN can help to increase the knowledge of how CB1954 
is reduced by FMN (Christofferson, 2009). Finally the NfsB protein was crystallized in 
order to produce a 3-D image of the enzyme via X-ray crystallography, illustrating the 
different bonds and interactions of the pro-drug with FMN (Nelson, 2011). 
The NfsB protein will benefit GDEPT as the enzyme pro-drug combination is already in 
cancer trial stages, due to its significant potential. Since the main issues lie in the lack of 
improving the NfsB preference for the CB1954 pro-drug, this project will mainly 
investigate the kinetics of NfsB with different substrates (CB1954 and menadione). 
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In this project the Wild type NfsB never his-tagged is referred to as WT NfsB. The wild 
type with the his-tag is referred to as WT HT NfsB and finally the wild type with the 
cleaved his-tag as WT CL NfsB. Finally the single unnatural amino acid mutant 
napthylalanine at position 124 of NfsB is referred to as NapA. However the NapA is also 
his-tagged as it is simply the WT HT NfsB protein but with the unnatural amino acid 
napthylalanine inserted at position 124. 
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1.1Summary of aims & objectives 
The aims and objectives were separated into three parts for the project.  
1. Comparing the activity & rate of reduction by WT NfsB , WT HT NfsB and WT CL 
NfsB; with the pro-drug CB1954 and Menadione 
This assessed the effect of the poly histidine tag on the rate of substrate reduction by NfsB. 
2. Comparing the rate of substrate reduction of NapA with WT NfsB 
This assessed whether the NapA shows an improvement for substrate reduction in 
comparison to the WT NfsB. 
3. Comparing the reduction of CB1954 and Menadione to determine whether Menadione 
is a better substrate for NapA than CB1954. 
This assessed whether Menadione is a better substrate for NapA than CB1954. 
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2. Materials & methods 
2.1 Material 
All reagents were bought from Sigma Aldrich unless otherwise stated 
2.2 Methods 
2.2.1 Over expression of NapA 
The clone expressing the NapA was a gift from Dr Ryan Mehl (Oregon State University, 
USA) and the protein was produced by the method described in the paper Jackson et al. 
2006. The cells were E. coli strain DH10B, transformed with the pBAD plasmid (with 
ampicillin antibiotic resistance) encoding the WT HT NfsB with the Phe124 codon 
mutated to UAG (previously a stop codon) and the pDule plasmid (with tetracycline 
antibiotic resistance) encoding the aminoacyl- tRNA synthetase/tRNACUA which 
will incorporate the appropriate unnatural amino acid when it recognises the stop codon 
(UAG). The E. coli cells were plated onto selective LB agar plates with antibiotics 
(Tetracycline 25 µg/ml & Ampicilin 100 µg/ml) and the plates were incubated for 24 
hours at 370 C.  A single colony from the agar plate was allowed to grow in 50 ml of LB 
media containing Tetracycline (25 µg/ml) and Ampicilin (100 µg/ml); this was placed in a 
shaking incubator at 370 C, and allowed to grow. Once it reached saturation, 2.5 ml of the 
culture was added to 500 ml of arabinose autoinduction media made up following the 
protocol in the paper Hammill et al, 2007, however with the following modifications: 
The addition of the fluorine probe (tfmF) to the auto-induction media in step 8 of the 
protocol was replaced with 1 mM Napthylalanine.  The optical growth curve for the E. coli 
with this medium had already been established by Martin Day, which was 23 hours until 
saturation. An optical density greater than 4 but less than 6 had to be obtained at 600 nm. 
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2.2.2 Over expression and purification of WT NfsB 
 
The WT NfsB with the poly histidine tag was expressed and purified by Martin Day on a 
nickel-nitrilotriacetic acid column (NiNTA) (Pharmacia Biotech). WT NfsB was purified 
previously as in the paper by Lovering et al 2001. 
2.2.3 Purification of NapA 
Cultures were harvested by centrifuging at 7,500 g for 10 minutes; the centrifuge cooled 
the cultures to approximately 4 0C. The supernatant was removed and the pellet re-
suspended in 30 ml of STE buffer (10 mM Tris pH 7.0, 100 mM NaCl, 1 mM EDTA). 
This was centrifuged at 7500 g for 30 minutes. The supernatant was removed again and re-
suspended in 30 ml buffer (10 mM Sodium Phosphate pH 7.0, 300 mM NaCl, 10 mM 
Imidazole, 20 µM FMN, and a EDTA free protease inhibitor (Roche). The enzyme mixture 
was sonicated (using Ultrasonic Processor Heat Systems) at level 5 (275 W) with each 
pulse cycle lasting 15 seconds on and off for 20 seconds (for 3 minutes). The sonicated 
enzyme mixture was then centrifuged for 30 minutes at 35,000 g and the supernatant 
filtered through Acrodisc Syringe Filter with a 0.2 µM Super Membrane (from Pall 
Corporations). 
Prior to column purification process, 200 µl of the protein solution was removed for 
purposes of SDS-PAGE in order to compare it to the protein after purification with the 
NiNTA column. 
The NiNTA column (Pharmacia Biotech) was pre-equilibrated with 10 mM Imidazole, 300 
mM NaCl, and 50 mM Sodium phosphate buffer; with a 100 mM NiNTA resin of 10 cm3 
volume.  The filtered supernatant was loaded onto the column and the fractions collected. 
Other proteins within the solution passed through the column; the NapA was bound on the 
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column, as the poly-histidine tag bound with the nickel ions immobilized on the resin. 
NapA was eluted from the column with a concentration gradient of Imidazole (20 – 200 
mM imidazole) in a buffer containing 50 mM sodium phosphate, 300 mM NaCl pH 8). 
The imidazole buffer was in a volume of 200 ml to which 20 µM of FMN was added. The 
flow rate of the column was 0.77 ml/minute, and 5.4 ml/fraction collected. 
2.2.4 SDS-PAGE 
The purity of WT NfsB, WT HT NfsB and WT CL NfsB was assessed via SDS-PAGE 
analysis. A Biorad  Protean II apparatus was used with  12% w/v acrylamide and 0.32% 
bisacrylamide. The gels contained HyperPAGE, a protein molecular marker from Bioline 
and the method from Laemmli, 1970 was followed (Laemmli, 1970). 
2.2.5 Small scale optimization of Recombinant Enterokinase cleavage of the poly 
histidine tag from WT HT NfsB 
The optimized conditions for cleavage of the WT HT NfsB with the recombinant 
enterokinase (rEK) purchased from Novagen were determined by conducting a small scale 
optimization (SSO). The SSO consisted of mixing 93 µl of rEK cleavage buffer (500 mM 
NaCl, 200 Mm Tris-HCl, 20 Mm CaCl2 at pH 7.4)  with  2 µl WT HT NfsB (13 mg/ml) 
and 5 µl of diluted rEK (1/50 dilution). The rEK and WT HT NfsB ratio is 0.001 Units 
(rEK): 260 µg WT HT NfsB (in a 100 µl). 
Furthermore following the same protocol, a small scale optimization with 0.0001 Unit of 
rEK : 260 µg WT HT NfsB (in a 100 µl) was conducted.  
Subsequently, 10 µl samples were taken to which 5 µl protein loading dye and 1 µl of 
PMSF (a protease inhibitor) were added.  The final concentration of the protein loading 
dye contained 50 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 1% β-mercaptoethanol, 
12.5 mM EDTA and 0.02 % bromophenol blue. The samples were taken at 2-4 hour 
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intervals (upt0 48 hours) and were stored in a -20 freezer. The samples were assessed by 
SDS-PAGE stained with Coomassie brilliant blue R. 
Once the optimum conditions were established, the poly histidine tag of the WT HT NfsB 
was cleaved using the following protocol: 
1 ml of NfsB (13 mg/ml) was added to 0.5 µl rEK (final ratio was 13 mg/ml WT HT NfsB: 
0.0005 Unit of rEK). The reaction was stopped at 24 hours using 1 µl of PMSF and 10 µl 
samples were taken (as for the optimization) from 0-24 hours. These were analysed by 
SDS-PAGE. Following the cleavage, the 1 ml of WT HT NfsB containing the rEK was 
loaded onto a NiNTA column in 10 mM Imidazole buffer containing 50 mM sodium 
phosphate, 300 mM NaCl pH 8 (Pharmacia Biotech). The ploy histidine tag from the WT 
HT NfsB bound to the nickel ions immobilized on the column and the WT CL NfsB eluted 
off the column. The fractions were collected and assessed by SDS-PAGE and Bradford 
assay.  
2.2.6 Protein concentration of all NfsB 
Protein concentrations of all NfsB samples were determined by Bradford assays, which 
were calibrated using bovine serum albumin (0-10 µg/ml).  
2.2.7 NapA activity assays 
The fractions of Napthylalanine NfsB with high protein concentration were pooled 
together and dialysed into 10 mM Potasium phosphate and 20 mM NaCl buffer pH 7.0 ( 
overnight at 4 0C). The dialysed protein was then concentrated using Amicon Spin 
Concentrator (with a 10 kDa membrane) to 2 ml.  
The activity assay was conducted to determine the specific activity of all the NfsB 
samples. The reaction consisted of 100 µM NADH and 200 µM menadione as the enzyme 
substrates, in the presence of 800 µM cytochrome C. The substrates were made up in 10 
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mM Tris-HCl pH 7.0 to a total volume of 1 ml in a quartz cuvette. The reaction was 
monitored by measuring the reduction of cytochrome C as each 2e- reduction of 
menadione to menadiol, results in 2 single e- reductions of cytochrome C. This was 
monitored at 550 nm using ε 21,100 M-1 cm-1. 
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2.2.8 Steady state enzyme kinetics 
This was performed with either menadione, or CB1954 as the variable substrate against a 
fixed concentration of NADH. 
For menadione kinetic studies, the reaction was performed in 10 mM Tris-HCl (pH 
7.0),with either  60 or 200 µM NADH, 1000 µM cytochrome C, 150 mM NaCl, 0.5 – 300 
µM menadione in 4% DMSO (the DMSO was  in 10 mM Tris pH 7). The reaction was 
initiated by adding approximately 10 nM of enzyme and the absorbance change measured 
at 550 nm on the Uvikon Spectrophotometer (Kontron instrument model 923). The molar 
absorbance for cytochrome c at 550 nm is ε 21,100 M-1 cm-1 , which was used to convert 
the absorbance change rate to change in concentration of product. The value is divided by 
2 as for every mole of menadione reduced; 2 moles of cytochrome C are also reduced.  
 
 
 
 
For CB1954 kinetic studies, the same procedure was followed with the following 
alterations: The menadione in DMSO was replaced with CB1954 (0.141 – 3.525 µM) in 
N-methyl pyrrolidone and Poly ethylene glycol 300 (2: 7 v/v  ratio) in a total volume of 50 
µl. The reaction was initiated by adding approximately 10 nM of enzyme and measured at 
420 nm on Uvikon Spectrophotometer (Kontron instrument model 923). This reaction 
monitored the reduction of CB1954 into its 2-/4- hydroxylamine derivative; the initial rate 
of CB1954 reduction per unit time was calculated.  The 2-/4- hydroxylamine have 
significantly different UV spectra, but at 420 nm the extinction coefficients for both are 
exactly the same. Therefore, allowing the reaction to be monitored at one wavelength. 
Activity change in absorbance/s-1        ÷2 
2,100 
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Furthermore at 420 nm the molar absorbance is ε 1,200 M-1 cm-1 , which was used to 
convert the absorbance change rate to change in concentration of product.  
 
 
 
 
 
2.2.9 Determination of the kinetic parameters 
 
The initial rate vi divided by the enzyme concentration [E] is plotted against the varying 
concentrations of menadione and CB1954.  This was then fitted to the following single 
substrate Michaelis Menten equation:  
 
  
 
  
 
 
 
 
 
 
 
Activity change in absorbance/s-1                                    
1,200 
Vi .   = 
[E]   
Kcatapp [A] 
KmAapp + [A] 
 
[E] = Enzyme concentration 
Vi = Initial rate of reduction 
[A] = Concentration of the variable substrate 
kcatapp = Apparant kcat 
KmAapp = Apparant Km for [A] at the concentration of [B] 
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Finally [A] is the variable substrate (CB1954 or menadione) and [B] is the constant 
substrate (NADH). Furthermore kcat/Km was accurately estimated using the following 
equation, as the apparent values kcat and Km depend on the concentration of the second 
fixed substrate (NADH). 
 
 
 
 
Figure 2.2.9.1:  Single substrate Michaelis Menten equation for the determination of 
kcat/Km 
 
The data was analysed by non-linear regression using SigmaPlot 11 and the P and t values 
were calculated. 
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2.2.10 Crystallization 
 
The proteins used for crystallization were WT HT NfsB and WT CL NfsB. The 
crystallization trays were set up using both a sitting and hanging drop vapour diffusion 
method.  
The tray used for the hanging drop vapour method was a 24 well tray from Molecular 
Dimensions Limited and all crystals were allowed to grow in 180 C. The conditions tried 
for the hanging drop vapour method were as the follows; the mother liquor was made up to 
a total of 1 ml, which consisted of PEG 4000 (10-20 %), Sodium acetate (10 mM pH 4.6), 
Nicotinic acid (15 mM pH 4.6), ethylene glycol (0-15 %) and finally filtered distilled 
water (to make up to 1 ml).  The trays used for the sitting drop vapour method was a 24 
well tray from Emerald Biosystem and all crystals were allowed to grow in 180 C.  The 
conditions tried for the sitting drop vapour method were as follows; the mother liquor was 
also made up to a total volume of 1 ml, which consisted of PEG 8000 (15-30 %),  either 
sodium acetate (0.6-10 Mm pH 4.6) or potassium phosphate (15-45 mM pH 7.0), ethylene 
glycol (0-15 %), additive (Na Maleate 50 mM). Finally filtered distilled water (to make up 
to 1 ml). Finally the drops of protein used for both the cover slip (hanging drop) and on the 
sitting wells (sitting drop) were 2 µl.  
2.2.11 Analysis of crystal structures and images 
Diffraction data was collected, for the WT CL NfsB on I04 at Diamond Light Source Ltd, 
Diamond House, Oxfordshire., UK by Martin Day; however these were not solved. 
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3. Results 
3.1 Expression and purification of WT NfsB, WT HT NfsB, WT CL NfsB and NapA 
Three different wild type NfsB proteins were investigated: Wild type NfsB which had 
never been his-tagged, wild type his-tagged NfsB which had been his-tagged and wild type 
NfsB with the his-tag cleaved off by using a recombinant enterokinase.  In this project the 
Wild type NfsB never his-tagged is referred to as WT NfsB. The wild type with the his-tag 
is referred to as WT HT NfsB and finally the wild type with the cleaved his-tag as WT CL 
NfsB. The single unnatural amino acid mutant napthylalanine at position 124 of NfsB is 
referred to as NapA. The vector used for incorporating the histidine tag into the protein is 
pTrcHisA, which added an NH2 terminal his6-tag, in order to allow affinity purification.  
The WT NfsB with the poly histidine tag was expressed and purified by Martin Day on a 
nickel-nitrilotriacetic acid column (NiNTA) (Pharmacia Biotech). WT NfsB was purified 
previously as in the paper by Lovering et al 2001. A Bradford assay was conducted to 
determine the protein concentration of the WT NfsB and WT HT NfsB, followed by SDS-
PAGE to assess purity and expression of protein. Furthermore 1 ml of the WT HT NfsB 
was cleaved with recombinant enterokinase to remove the his-tag and produce the WT CL 
NfsB, which was purified using a NiNTA column and followed by a Bradford assay to 
determine the protein concentration. Finally a SDS-PAGE was conducted for assessing the 
purity of the sample and also whether the his-tag was removed successfully. 
The NapA was expressed as in the paper hammill et al, 2007 (refer to method 2.2.1) and 
purified using a NiNTA column, followed by a Bradford assay and SDS-PAGE. 
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The WT HT NfsB has a known molecular weight of around 23 kDa and the SDS-PAGE 
gel illustrated that the NfsB protein was present and quite pure in all WT NfsB, WT HT 
NfsB and WT CL NfsB samples. However the NapA was significantly impure and the 
NfsB band was very faint. In addition the NfsB band which had appeared for the NapA 
was significantly lower than the normal molecular weight expected for NfsB. Furthermore, 
once the his-tag had been removed, the molecular weight of the WT HT NfsB should 
decrease and produce a slight lower (by 1-2 kDa) NfsB band (figure 3.1 1). 
 
 
 
 
 
 
 
 
Figure 3.1.1: A 12% w/v acrylamide and 0.32% bisacrylamide gel for the purity of the 
NfsB samples. 
The molecular marker from bioline is on lane 1. The WT HT NfsB, is on lane 2 with a 
1/20 dilution.  The WT CL is on lanes 3 (in acetate buffer) and on lane 4 (in phosphate 
buffer), both diluted 1/5. Lanes 5 and 6 contain other purified WT NfsB samples. The 
undiluted NapA is on lanes 7 and 8.   
 
 
WT HT NfsB 
slightly higher 
band  
WT CL NfsB 
slightly lower 
band 
WT NfsB  
slightly lower band  
NapA 
faint, impure streaked lane and lower band 
than normal NfsB 
band ) 
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3.2 Cleavage of the poly histidine tag from WT HT NfsB with recombinant 
enterokinase 
Prior to cleaving the his-tag off the WT HT NfsB with the recombinant enterokinase 
(rEK), the optimized incubation time and rEK concentration were established by 
conducting a small scale optimization to determine optimum conditions, followed by a 
large scale to remove the his-tag from the WT HT NfsB. Furthermore the optimized 
conditions for digestion of the NfsB with the recombinant enterokinase were established 
and analysed using SDS-PAGE, where the concentration and incubation time of the rEK 
were varied. 
The gel on figure 3.2.1 contains the rEK at 0.001 Units and 260 µg/ml WT HT NfsB, 
where samples were taken from zero to 48 hours. The gel shows significant secondary 
digestion of the protein as many lower bands have appeared on the gel confirming further 
unwanted proteolysis at secondary sites. However a band has appeared below the NfsB 
band at 23 kDa, confirming the his-tag was removed from the WT HT NfsB; although 
before 4 hours there is no digestion and after 28 hours the digestion stops (figure 3.2.1). 
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Figure 3.2.1: A 12% w/v acrylamide and 0.32% bisacrylamide gel, for the optimization of 
rEK digestion of WT HT NfsB with high rEK concentration. 
Digestion times with rEK:  
Lane1: zero hours, lane2: 2 hours, lane3: Marker (Bioline), lane4: 4 hours, lane5: 22.5 
hours, lane6: 24.5 hours, lane7: 26.5, lane8: 28.5, lane9: 46 hours, lane10: 48 hours 
 
 
 
 
 
 
 
 
Secondary 
digestion 
Digestion of his-tag; lower band appeared 
Digestion stops 
No digestion 
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The concentration of the rEK was too high which caused unwanted proteolysis; therefore 
another optimization was carried as before however only 0.0001 Units of rEK was used in 
a ratio with 260 µg/ml WT HT NfsB. The samples were taken as before and assessed by 
SDS-PAGE (figure 3.2.2). The gel illustrates that there wasn’t enough rEK present to fully 
digest the WT HT NfsB sample, however although the bands are very faint, the digestion 
of the his-tag can still be seen after 4 hours and in an excess of 22 hours the digestion 
stops. 
 
 
 
 
 
 
 
 
 
Figure 3.2.2: A 12% w/v acrylamide and 0.32% bisacrylamide gel, for the optimization of 
rEK digestion of WT HT NfsB with low rEK concentration. 
Digestion times with rEK:  
Lane one: molecular Marker (Bioline), lane2: zero hour, lane3: 2 hours, lane4: 4 hours, 
lane5: 20 hours, lane6: 22 hour, lane7: 24 hours, lane8: 43 hours, lane9: 46 hours 
From these optimizations, the optimum conditions were determined, which was an 
incubation time for at least 22 hours (to ensure the his-tag is removed from all NfsB) and a 
No digestion Faint but slight digestion of 
his-tag . The rEK concentration 
is too low 
No secondary 
digestion 
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concentration of 0.0005 Units for the rEK (this is an average of the two optimizations as 
one was too high and the other too low). By using these conditions 1 ml of the WT HT 
NfsB was incubated with 0.0005 Units of rEK for 24 hours and the reaction was stopped 
with PMSF.  As for the optimization, samples were taken in order to monitor the digestion 
of the his-tag by SDS-PAGE (figure 3.2.3). This showed that the his-tag was successfully 
digested as a lower band appeared below the NfsB band, confirming digestion. 
 
 
 
 
 
 
 
 
Figure 3.2 .3: A 12% w/v acrylamide and 0.32% bisacrylamide gel of the digestion of the 
WT HT NfsB.  
Digestion times with Rek: 
In lane one is the Marker (Bioline), lane 2: zero hours, lane 3: 2 hours, lane 4: 4 hours, lane 
5: 20 hours, lane 6: 21 hours, lane 7: 24 hours. 
Finally the digested wild type NfsB protein was loaded onto a NiNTA column, which was 
subsequently followed by a SDS-PAGE of the fractions collected (figure 3.2.4). This 
illustrated that the his-tag had been successfully cleaved as the lower histidine band was 
observed on the SDS-PAGE. However there were still two bands on the gel following 
purification with the NiNTA column. This indicates that not all of the WT HT NfsB 
protein had been cleaved successfully (figure 3.2.4/5). 
Lower band below NfsB band: Digestion of His-tag 
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Both figures illustrate fractions of WT CL NfsB after purification with a NiNTA column. 
There are still two bands which conclude that the his-tag was not removed from all of the 
NfsB protein within the WT CL NfsB samples. 
 
 
 
 
 
 
 
 
 
Figure 3.2.4:  A 12% w/v acrylamide and 0.32% bisacrylamide gel of the WT CL NfsB 
Lane1: Marker, Lane 2: Purified NfsB with His-tag, Lane 3: NfsB + rEk at zero hours, 
Lane 4: fraction 4, Lane 5: fraction 5, Lane 6: fraction 6, Lane 7: fraction7, Lane 8: 
fraction 8, Lane 9 and 10: fraction 9 
 
 
 
 
 
Lower band illustrating cleaved hist-tag 
but after purification the upper band 
should have been removed 
Purified WT HT NfsB 
illustrating a higher NfsB band 
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Figure 3.2.5:  A 12% w/v acrylamide and 0.32% bisacrylamide gel of the WT CL NfsB  
Lane1: Marker, Lane 2: Purified NfsB with His-tag, Lane 3: NfsB + rEK at zero hours, 
lane 4: fraction 10, Lane 5: fraction 12, Lane 6: fraction 13, Lane 7: fraction 14, Lane 8: 
fraction 15, Lane 9: fraction 16, Lane 10: fraction 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lower band illustrating 
cleaved hist-tag but after 
purification the upper band 
should have been removed 
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3.3The steady state kinetics of all NfsB proteins for CB1954; the effects of the poly 
histidine tag on the rate of CB1954 reduction 
Steady state kinetics was conducted for the three NfsB proteins in order to assess whether 
the his-tag had an effect on the rate of CB1954 reduction by the protein in the presence of 
cytochrome C. For each of the kinetic assay, a constant NADH concentration of either 60 
µM or 200 µM was used and a varied concentration of the pro-drug CB1954 (141-3525 
µM).   
This reaction monitored the reduction of CB1954 into its 2-/4- hydroxylamine derivative; 
the initial rate of CB1954 reduction per unit time was calculated at 420 nm ε 1,200 M-1 cm-
1 , which was used to convert the absorbance change rate to change in concentration of 
product. Furthermore the kcat/Km was estimated from the fit of each dataset to the 
Michaelis Menten equation on figure 2.2.9 1. (The kinetic parameter tables can be found in 
Appendix I section 1). 
Finally, NADH is required as the reducing agent to reduce FMN which will subsequently 
reduce the substrate (CB1954), therefore the more NADH present in the reaction, the 
higher the Km value as well as the rate of reduction.   
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Figure 3.3.1: The rate of CB1954 reduction by the WT NfsB at fixed 60 µM (red) and 200 
µM (black) NADH concentrations, fitted to the equation on figure 2.2.9 1  
This plots initial rate of CB1954 reduction by WT NfsB (vi) divided by the enzyme 
concentration [E] using 60 or 200 µM NADH (as the cofactor) at a range of CB1954 
concentrations. The lower concentration of NADH (red 60 µM), illustrates the line curving 
(fitted to a hyperbola), as Km is reached. However there is substrate inhibition as high 
concentration levels of CB1954 are used. Furthermore with the higher NADH 
concentration (black 200 µM) the line is linear which indicates that Km is very high and 
that the line shown is presenting the initial rate of reaction of the hyperbola.  
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Figure 3.3.2: The rate of CB1954 reduction by the WT HT NfsB at fixed 60 µM (red) and 
200 µM (black) NADH concentrations, fitted to the equation on figure 2.2.9.1 
This plots initial rate of CB1954 reduction by WT HT NfsB (vi) divided by the enzyme 
concentration [E] using 60 or 200 µM NADH (as the cofactor) at a range of CB1954 
concentrations. 
The lower concentration of NADH (red 60 µM), illustrates a linear line, however at 3525 
µM CB1954 it begins to curve. The higher NADH concentration (black 200 µM) has a 
linear rate of reduction which indicates that Km is very high and that the line shown is 
presenting the initial rate of reaction of the hyperbola.  
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Figure 3.3.3: The rate of CB1954 reduction by the WT CL NfsB at fixed 60 µM (red) and 
200 µM (black) NADH concentrations, fitted to the equation on figure 2.2.9.1 
 
This plots initial rate of CB1954 reduction by WT CL NfsB (vi) divided by the enzyme 
concentration [E] using 60 or 200 µM NADH (as the cofactor) at a range of CB1954 
concentrations. 
The lower concentration of NADH (red 60 µM), illustrates the line beginning to curve and 
thus beginning to reach Km , however the higher NADH concentration (black 200 µM) 
illustrate a linear line, which indicates that Km  is very high and that the line shown is 
presenting the initial rate of reaction of the hyperbola..  
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3.4 Statistical analysis of the poly-histidine tag’s effect on the rate of CB1954 reduction 
 
From observing the figures 3.3.1-3, it can be observed that the addition of the his-tag 
slightly decreases the rate of CB1954 reduction by the NfsB protein. However in order to 
determine this accurately a Mann-Whitney U Rank Sum Test was conducted as the sample 
sizes were not the same and the normality test failed. This concluded that when comparing 
the values observed for WT NfsB and WT HT NfsB for the rate of reduction of the pro-
drug, there was no statistical significant difference (P= 0.986 for 60 µM NADH and P= 
0.617 for 200 µM NADH). 
Furthermore once cleaved there was no statistical significance observed when comparing 
to the values observed for WT NfsB (P= 0.836 for 60 µM NADH and P= 0.127 for 200 
µM NADH). 
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3.5 The steady state kinetics of WT NfsB, WT HT NfsB, WT CL NfsB for Menadione 
to determine the effects of the poly histidine tag on the rate of substrate reduction 
 
Steady state kinetics was conducted for the three NfsB proteins in order to assess whether 
the his-tag had an effect on the rate of menadione reduction by the protein in the presence 
of cytochrome C. For each of the kinetic assays, a constant NADH concentration of either 
60 µM or 200 µM was used and the concentration of the substrate (menadione) was varied 
(0.5-300 µM).  The reaction was monitored by measuring the reduction of cytochrome C 
as each 2e- reduction of menadione to menadiol, results in 2 single e- reductions of 
cytochrome C. This was monitored at 550 nm using ε 21,100 M-1 cm-1. Furthermore the 
kcat/Km were estimated from the fit of each dataset to the Michaelis Menten equation on 
figure 2.2.9.1. (The kinetic parameter tables can be found in Appendix I section 2). 
Finally, NADH is required as the reducing agent to reduce FMN which will subsequently 
reduce the substrate (menadione), therefore the more NADH present in the reaction, the 
higher the Km value as well as the rate of reduction 
For all the graphs illustrating the rate of Menadione reduction by the three NfsB 
proteins: 
This plots initial rate of menadione reduction by NfsB (vi) divided by the enzyme 
concentration [E] using 60 or 200 µM NADH (as the cofactor) at a range of menadione 
concentrations (0.5-300 µM) 
Both the higher and lower concentration of NADH used for the rate of menadione 
reduction, illustrate a good fit to the hyperbola curve and thus Km has been reached; 
menadione is a better substrate than CB1954 for all NfsB proteins. 
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Figure 3.5.1: The rate of Menadione reduction by the WT NfsB at fixed 60 µM (red) and 
200 µM (black) NADH concentrations, fitted to the equation on figure 2.2.9.1 
This plots initial rate of menadione reduction by WT NfsB (vi) divided by the enzyme 
concentration [E] using 60 or 200 µM NADH (as the cofactor) at a range of menadione 
concentrations. 
Both the concentration of NADH (red 60 and black 200 µM), illustrates the 
product/substrate inhibition of menadione reduction. 
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Figure 3.5.2: The rate of Menadione reduction by the WT HT NfsB at fixed 60 µM (red) 
and 200 µM (black) NADH concentrations, fitted to the equation on figure 2.2.9.1 
This plots initial rate of menadione reduction by WT HT NfsB (vi) divided by the enzyme 
concentration [E] using 60 or 200 µM NADH (as the cofactor) at a range of menadione 
concentrations. 
Both the concentration of NADH (red 60 and black 200 µM), illustrates the 
product/substrate inhibition of menadione reduction. 
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Figure 3.5.3: The rate of Menadione reduction by the WT CL NfsB at fixed 60 µM (red) 
and 200 µM (black) NADH concentrations fitted to the equation on figure 2.2.9.1 
This plots initial rate of menadione reduction by WT CL NfsB (vi) divided by the enzyme 
concentration [E] using 60 or 200 µM NADH (as the cofactor) at a range of menadione 
concentrations. 
The higher concentration of NADH (black 200 µM), illustrates the product/substrate 
inhibition of menadione reduction. However due to the standard error being very high for 
the last two values recorded for the lower concentration of NADH (red 60 µM), the 
substrate inhibition cannot be observed. 
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3.6 Statistical analysis of the poly-histidine tag’s effect on the rate of Menadione 
reduction 
 
From observing the figures 3.5.1-3, it can be observed that the addition of the his-tag 
slightly decreases the rate of menadione reduction by the NfsB protein. However in order 
to determine this accurately a Two tailed T-Test was conducted.  
This concluded that when comparing the values observed for WT NfsB and WT HT NfsB 
for the rate of reduction of the pro-drug, there was no statistical significant difference (P= 
0.202 for 60 µM NADH and P= 0.098 for 200 µM NADH). 
However once cleaved there a statistical significance observed when comparing to WT 
NfsB, and the difference in the median values between the two groups is greater than that 
which would be expected by chance (P= <0.001 for 60 and 200 µM NADH). 
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3.7 The steady state kinetics of NapA for the pro-drug CB1954 
 
Steady state kinetics was conducted for the NapA with the pro-drug CB1954, in order to 
assess whether NapA has better kinetics with CB1954 in comparison to the WT NfsB 
proteins. For the kinetic assay, a constant NADH concentration of either 60 µM or 200 µM 
was used and the concentration of the substrate (CB1954) was varied (141-3525 µM).   
The reaction monitored the reduction of CB1954 into its 2-/4- hydroxylamine derivative; 
the initial rate of CB1954 reduction per unit time was calculated at 420 nm ε 1,200 M-1 cm-
1 , which was used to convert the absorbance change rate to change in concentration of 
product. Furthermore the kcat/Km was estimated from the fit of each dataset to the 
Michaelis Menten equation on figure 2.2.9 1. (The kinetic parameter tables can be found in 
Appendix I section 3). 
Finally NADH is required as the reducing agent to reduce FMN which will subsequently 
reduce the substrate CB1954, therefore the more NADH present in the reaction, the higher 
the Km value as well as the rate of reduction. 
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Figure 3.7 .1 : The rate of CB1954 reduction by the NapA at fixed 60 µM (black) and 200 
µM (red) NADH concentrations, fitted to the equation on figure 2.2.9 1. 
This plots initial rate of CB1954 readuction by NapA (vi) divided by the enzyme 
concentration [E] using 60 or 200 µM NADH (as the cofactor) at a range of CB1954 
concentrations.  
 The rate of CB1954 reduction is very significantly low. However the NapA was not pure 
and there wasn’t much of the protein present in the sample, hence the high standard error 
each recording. 
64 
 
3.8 The steady state kinetics of NapA for Menadione 
 
Steady state kinetics was conducted for the NapA with the menadione, in order to assess 
whether NapA has improved kinetics with menadione in comparison with CB1954. For the 
kinetic assay, a constant NADH concentration of either 60 µM or 200 µM was used and 
the concentration of the substrate (menadione) was varied (0.5-100 µM).  The reaction was 
monitored by measuring the reduction of cytochrome C as each 2e- reduction of 
menadione to menadiol, results in 2 single e- reductions of cytochrome C. This was 
monitored at 550 nm using ε 21,100 M-1 cm-1. Furthermore the kcat/Km were estimated from 
the fit of each dataset to the Michaelis Menten equation on figure 2.2.9.1 (The kinetic 
parameter tables can be found in Appendix I section 4). NADH is required as the reducing 
agent to reduce FMN which will subsequently reduce the substrate CB1954, therefore the 
more NADH present in the reaction, the higher the Km value as well as the rate of 
reduction. 
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Figure 3.8.1: The  rate of Menadione reduction by the single amino acid mutant 
Napthylalanine NfsB at fixed 60 µM (red) and 200 µM (black) NADH concentrations, 
fitted to the Michaelis Menten equation  (figure 2.2.9.1) 
This plots initial rate of menadione reduction by NapA (vi) divided by the enzyme 
concentration [E] using 60 or 200 µM NADH (as the cofactor) at a range of menadione 
concentrations.  
 The rate of menadione reduction is significantly higher than the rate of CB1954 reduction 
by NapA.  
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3.9 Statistical analysis comparing the rates of Menadione and CB1954 reduction by NapA 
 
From observing the figures 3.6.1 and 3.7.1, it can be observed that the rate of menadione 
reduction is higher than that of CB1954 by NapA. In order to determine this accurately a 
Mann-Whitney U Rank Sum Test was conducted as the sample sizes were not the same 
and the normality test failed. This concluded that at 60 µM NADH there is no statistically 
significant difference between the rates of menadione and CB1954 by NapA (P= 0.843). 
However at 200 µM NADH there was a statistically significant difference observed 
concluding that the difference in median values observed for the rates of menadione and 
CB1954 by NapA is greater than that which would be expected by chance (P=0.032). 
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4. Crystal structures and diffraction pattern 
 
Crystal trays were set up using the His-tagged and cleaved wild type NfsB via the sitting 
and hanging drop vapour methods and the crystals were allowed to grow in a 
crystallization room at 18 0C.  The His-tagged NfsB did not crystallize through either 
method; however the cleaved wild type NfsB crystallized using both methods. The crystal 
which formed in the sitting drop method was in mother liquor consisting of 15 mM 
Nicotinic acid, 10 mM Sodium acetate, 20 % of PEG 4000, 5 % ethylene glycol and made 
up to 1 ml with filtered distilled water (figure 4.1). 
 
Figure 4.1: The cleaved wild type NfsB crystal in acetate buffer (hanging drop vapour 
method)  
This is a crystal of the wild type NfsB; however the crystal appears to be twined where two 
or more separate crystals are sharing the same crystal lattice points; the image illustrates an 
intergrowth of several crystals.  
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The cleaved wild type NfsB crystal which formed using the sitting drop methods was in a 
mother liquor consisting of 10 mM Nicotinic acid, 10 mM Sodium acetate, 22 % PEG 
8000, 15 % ethylene glycol, 50 mM Sodium Maleate and filtered distilled water made up 
to 1 ml. 
 
 
Figure 4.2: The crystals formed by cleaved wild type NfsB in acetate buffer (sitting drop 
vapour method). The crystals are clustered and did not grow efficiently. 
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Furthermore only the crystal from figure 4.1 diffracted, however due to the intergrowth of 
lattices the diffraction pattern could not be solved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: The diffraction pattern of the cleaved wild type NfsB crystal in acetate buffer 
(hanging drop vapour method). 
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5. Discussion 
 
The main aims in this study were to assess the following: 
a) Whether menadione is a better substrate for NapA than CB1954 
b) Whether NapA shows an improvement for substrate reduction in comparison to the 
WT NfsB 
c) The effect of the poly histidine tag on the rate of substrate reduction by the three 
NfsB proteins.  
In this project the Wild type NfsB never his-taggded is referred to as WT NfsB. The wild 
type with the his-tag is referred to as WT HT NfsB and finally the wild type with the 
cleaved his-tag as WT CL NfsB. The single unnatural amino acid mutant napthylalanine at 
position 124 of NfsB is referred to as NapA. However the NapA is also his-tagged as it is 
simply the WT HT NfsB protein but with the unnatural amino acid napthylalanine inserted 
at position 124. 
The concentration of NapA protein obtained was significantly low and impure (figure 
3.1.1). In addition there was a low molecular weight band observed on the SDS-PAGE, 
which was potentially due to truncated proteins; there were some proteins made which 
terminated at the stop codon (UAG). This would then translate on the gel as a high 
mobility band; however this can be resolved by using a C terminal affinity tag, which will 
only purify the full length proteins as the C terminal is at the end of the protein; therefore 
any truncated proteins will be removed (Hammill et al, 2007). Furthermore in order to 
ensure that the band obtained for the NapA on the SDS-PAGE is actually the protein, an 
inhibitor such as Dicoumarol can be used which will reduce the rate of substrate reduction 
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by NapA. If the rate is not reduced significantly, then the protein present in the sample is 
not NapA as this would have been inhibited (Rau and Stolz, 2003).  
The specificity constant (kcat/Km) of NapA with the pro-drug, measured how efficiently 
NapA reduced the substrate. As the results showed that rate of CB1954 reduction by NapA 
was very very low, the kcat/Km were also very low (figure 5.1: at 60 µM NADH= 0.0008 ± 
0.0004 and at 200 µM NADH= 0.0005 ± 0.0002). The complete kinetic parameter table 
can be found in Appendix I section 3.   
 
Nevertheless, the specificity constant for NapA with menadione was considerably higher 
than that with CB1954. In addition the Mann-Whitney U Rank Sum Test, which concluded 
that at 200 µM NADH there was a statistically significant difference observed concluding 
that the difference in median values observed for the rates of menadione and CB1954 by 
NapA is greater than that which would be expected by chance (P=0.032). However at 60 
µM NADH there is no statistically significant difference between the rates of menadione 
and CB1954 by NapA (P= 0.843). Moving on, as the NapA was not pure and may have 
contained other proteins, the UV spectrum test should be conducted (and the steady state 
enzyme kinetics repeated. This would allow verification of the results and viability of the 
concluded theory that menadione is a better substrate for NapA. 
Although the pro-drug is not a natural substrate for the enzyme, studies have shown that 
NapA has a higher specificity constant in comparison to the WT NfsB (Jackson et al, 
2006; Grove et al, 2003).  However in this project NapA has a lower specificity constant in 
comparison to the WT NfsB, which was due to the low expression of NapA in this study 
and the impurity within the sample.  
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Another explanation could be that there wasn’t enough FMN bound to the enzyme and 
thus NapA could not reduce the substrate efficiently. To assess the level of bound FMN 
and NapA, a UV spectrum could be conducted at 280, 355 and 455 nm. The NapA and 
FMN, which can be bound or unbound, will give a peak at 280 nm, the FMN (unbound) 
will give a peak at 355 and finally the NapA (unbound) will give a peak at 455 nm. A 
normal and expected result would show a 4 x difference in the peaks observed at 280 and 
355 nm. Finally by subtracting the values obtained for the unbound NapA (455nm) and 
unbound FMN (355 nm) from the peak which contains both bound/unbound FMN and 
NapA, the level of bound FMN can be determined (Hammill et al, 2007).  
 
The SDS-PAGE illustrated that the WT NfsB, WT HT NfsB and WT CL NfsB were quite 
pure, however the main issue lies within whether the his-tag was successfully cleaved off 
the WT HT NfsB. The purified digested WT HT NfsB was assessed by SDS-PAGE and 
illustrated that only part of the protein had been cleaved. This could have been due to (i) 
that the protein was actually not digested enough; however (ii) it was more likely due to 
the column which did not remove the digested his-tag successfully (figure 3.2.4). This 
could be assessed by loading the digested sample on another NiNTA column and 
observing the fractions on a SDS-PAGE, in order to be certain of the results. 
Moreover, the specificity constant of the three wild type proteins for the reduction of 
CB1954 were all quite low as the pro-drug is not a natural substrate for the NfsB (figures 
5.1a/b). 
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The his-tag had a negative effect on the specificity constant, for example at 60 µM NADH, 
the kcat/Km value observed for the WT NfsB (0.0041) is double the kcat/Km value for WT 
HT NfsB (0.0022). Also once the his-tag is cleaved of the WT HT NfsB, the specificity 
constant increases, but doesn’t fully regain the full efficiency of reducing the substrate 
(0.0026). A Similar pattern of results is also observed for 200 µM NADH (figures 5.1a/b). 
The vector used for incorporating the histidine tag into the protein is pTrcHisA, which 
added a NH terminal his6-tag, in order to allow affinity purification. However the active 
site for the NfsB and sites which can interfere with the binding of the FMN cofactor and 
substrates is located near the N-terminal of the NfsB protein. Therefore the poly histidine 
tag could be interfering with the interaction between the substrate and the FMN cofactor. 
This would then result in a lower specificity constant observed for the WT HT NfsB in 
comparison to the WT NfsB (Rau and Stolz, 2003; Grove et al, 2003; Jackson et al, 2006). 
Furthermore, there is a slight increase in the specificity constant once the his-tag has been 
removed, however the value does not return to its original level. This is because the his-tag 
on the pTrcHisA vector is located between the bases 425-442, and the recombinant 
enterokinase cleaves the his-tag at the bases 491-505. Therefore there are several bases of 
the histidine tag left on the NfsB and some extra bases of the vector are cut. As the 
complete histidine tag is not removed, it is expected that the specificity constant will not 
be restored to the original level (Rau and Stolz, 2003). 
To conclude whether there is an actual negative effect caused by the addition or the 
cleavage of the histidine tag, a Mann-Whitney U Rank A Sum Test was conducted, which 
concluded that in the case of NfsB reduction of CB1954 the histidine tag had no significant 
effect (P> 0.05). However in the case of menadione reduction,  once cleaved there was a 
statistical significance observed when comparing to WT NfsB, and the difference in the 
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median values between the two groups is greater than that which would be expected by 
chance (P= <0.001 for 60 and 200 µM NADH). 
Finally, although there is no statistical significance observed, in order to investigate why 
there is a higher specificity constant for the rate of menadione reduction with all the NfsB 
proteins a crystal structure of menadione with NfsB is essential. As this would determine 
how menadione interacts with the FMN cofactor, and the differences in this interaction 
which causes it to be a better substrate than CB1954. 
The twinned crystal which was obtained from the WT CL NfsB could not be solved 
although it did diffract. This was due to several crystals sharing the same lattice points and 
thus causing an intergrowth of crystals. Generally in order to solve the diffraction pattern 
of a crystal, twinning can be a major problem as the different patterns of reflection from 
the crystal (as it is rotated and the diffraction pattern of each angle is collected) is from 
several crystals and thus nearly impossible to solve. The main system to solve a crystal as 
such is to obtain several crystals and therefore have multiple diffraction patterns which can 
then help solve the diffraction pattern and subsequently produce the crystal structure image 
(Nelson, 2011). 
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Figure 5.1a: The specificity constants for all NfsB proteins for the reduction of CB1954 
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Figure 5.1b: The specificity constants for all NfsB proteins for the reduction of menadione 
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6. Conclusion and recommended further research 
 
The conclusion of this project is that the histidine tag has an inhibitory effect on the 
specificity constant of the wild type NfsB for the substrates (CB1954 and menadione). 
However, statistically the histidine tag has only an inhibitory effect on the rate of 
menadione reduction. Furthermore menadione is a better substrate for NapA in comparison 
to CB1954, however to ensure this result is highly accurate; a repeat of NapA expression 
and purification is highly advisable in order to obtain viable results. Also the use of a 
cleavage enterokinase which cuts the entire histidine tag should be compared with the rEK 
used in this study, and whether the complete removal of the his-tag improves the 
specificity constant for the WT CL NfsB significantly. Finally, X-ray crystallography of 
menadione with NfsB would be extremely important in order to conclude why it is a better 
substrate for NfsB and subsequently, based on these results, improve NfsB activity with 
CB1954. 
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Appendix I 
Section 1: The steady state kinetics of WT NfsB for the pro-drug CB1954 ; the effects of the 6 poly histidine tag on the rate of substrate 
reduction 
 
Table 1.1 The kinetic parameters of reduction of the pro-drug CB1954 by the WT  NfsB.   
Table 1.2 : The kinetic parameters of reduction of the pro-drug CB1954 by WT HT NfsB.   
 
 
[CB1954] μM 
 
[NADH] μM 
 
kcatapps
-1 
 
t 
 
P 
 
Kmapp μM 
 
t 
 
P 
 
Kcat/Km μM
-1s-1 
 
t 
 
P 
 
141-3525 
 
60 
 
5.8 ± 1.2 
 
4.6 
 
0.0004 
 
1400  ± 700 
 
1.9 
 
0.067 
 
0.0041 ±  0.0013 
 
3.2 
 
0.0058 
 
141-3525 
 
200 
 
26  ± 3.5 
 
7.4 
 
<0.0001 
 
9900  ±1700 
 
5.8 
 
<0.0001 
 
0.0026 ±  0.000099 
 
26 
 
<0.0001 
 
[CB1954] μM 
 
[NADH] μM 
 
kcatapps
-1 
 
t 
 
P 
 
Kmapp μM 
 
t 
 
P 
 
Kcat/Km μM
-1s-1 
 
t 
 
P 
 
141-3525 
 
 
60 
 
10.7  ±  3.4 
 
3.1 
 
0.0064 
 
4800  ± 2200 
 
2.1 
 
0.052 
 
0.0022 ±  0.0004 
 
6.0 
 
<0.0001 
 
141-3525 
 
 
200 
 
ND 
 
- 
 
- 
 
ND 
 
- 
 
- 
 
0.0019 ±  0.0002 
 
8.4 
 
<0.0001 
NfsB + No  His-tag 
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Table 1.3: The kinetic parameters of reduction of the pro-drug CB1954 by the WT CL NfsB.   
For all the kinetic parameters of wild type NfsB with CB1954, the  pro-drug concentration was varied between 141 - 3525 µM with a fixed 
concentration of either 60 or 200 µM NADH. The kinetic parameters were estimated from the fit of each dataset to the Michaelis Menten 
equation (Figure 2.2.9 1). 
 
 
 
 
 
 
[CB1965] μM 
 
[NADH] μM 
 
kcatapps
-1 
 
t 
 
P 
 
Kmapp μM 
 
t 
 
P 
 
Kcat/Km μM
-1s-1 
 
t 
 
P 
 
141-3525 
 
 
60 
 
9.5 ± 2.3 
 
4.2 
 
0.0011 
 
3700 ±1400 
 
2.6 
 
0.020 
 
0.0026 ± 0.00040 
 
6.8 
 
<0.0001 
 
141-3525 
 
 
200 
 
ND 
 
- 
 
- 
 
ND 
 
- 
 
- 
 
0.0032 ± 0.0004 
 
8.5 
 
<0.0001 
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 Section 2: The steady state kinetics of WT NfsB for Menadione; the effects of the 6 poly histidine tag on the rate of substrate reduction 
Table 2.1 : The kinetic parameters of reduction of the Menadione by the WT NfsB.   
Table 2.2: The kinetic parameters of reduction of the Menadione by the WT HT NfsB.   
 
 
[Menadione] μM  
 
[NADH] μM 
 
kcatapps
-1 
 
t 
 
P 
 
Kmapp µM 
 
t 
 
P 
 
Kcat/Km μM
-1s-1 
 
t 
 
P 
 
0.5-300 
 
60 
 
5.8 ± 0. 44
  
 
13 
 
<0.0001 
 
4.2  ± 1.6 
 
2.6 
 
0.018 
 
1.4  ± 0 .47 
 
2.9 
 
0.0079 
 
0.5-300 
 
200 
 
13  ± 0.69  
 
19 
 
<0.0001 
 
18  ±  3.3 
 
5.4 
 
<0.0001 
 
0.75  ± 0.11 
 
6.6 
 
<0.0001 
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[NADH] μM 
 
kcatapps
-1 
 
t 
 
P 
 
Kmapp μM 
 
t 
 
P 
 
Kcat/Km μM
-1s-1 
 
t 
 
P 
 
0.5-300 
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6.2  ±  0.5 
 
14 
  
 
<0.0001 
 
15  ±  4 
 
3.7  
 
0.0016 
 
0.42 ±  0.095 
 
4.5  
 
0.0002 
 
0.5-300 
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13  ±  0.6 
 
22  
 
<0.0001
  
 
41 ± 5.5
 
  
 
7.4  
 
<0.0001 
 
0.32 ±  0.032 
 
9.8 
 
<0.0001
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Table 2.3: The kinetic parameters of reduction of the Menadione by the WT CL NfsB.   
 
The Menadione concentration is varied between 0.5 - 300 µM with a fixed concentration of either 60 or 200 µM NADH. The kinetic parameters 
were estimated from the fit of each dataset to the Michaelis Menten equation figure 2.2.9.1 
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9.3  ±  0.47
  
 
20 
 
<0.0001 
 
17  ±  3.1
  
 
5.4 
 
<0.0001 
 
0.56  ±  0.085  
 
6.6 
 
<0.0001 
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Section 3: The steady state kinetics of  NapA for the pro-drug CB1954 
 
 
Table 3.1: Displaying the kinetic parameters of reduction of the CB1954 by the NapA.   
For the steady state kinetics of  Napthylalanine NfsB with CB1954, the pro-drug concentration is varied between 141 - 3525 µM with a fixed 
concentration of either 60 or 200 µM NADH. The kinetic parameters were estimated from the fit of each dataset to the Michaelis Menten 
equation (figure 2.2.9.1). 
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1.2 ± 0.48
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ND 
 
- 
 
- 
 
0.0005 ±0.0002   
 
2.8 
 
0.015 
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Section 4: The steady state kinetics of NapA for Menadione 
Table 4.1: Displaying the kinetic parameters of reduction of Menadione by the NapA.   
For the above table, the Menadione concentration is varied between 0.5-100 µM with a fixed concentration of either 60 or 200 µM NADH. The 
kinetic parameter were estimated from the fit of each dataset to the Michaelis Menten equation (figure 2.2.9.1). 
 
 
 
 
[Menadione] μM  
 
 
[NADH] Μm 
 
kcatapps
-1 
 
t 
 
P 
 
Kmapp μM 
 
t 
 
P 
 
Kcat/Km μM
-1s-1 
 
t 
 
P 
 
0.5 – 100 
 
 
60 
 
0.34  ± 0.012
  
 
28 
  
 
<0.0001 
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1.5  ±  0.21
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9900  ± 
1700 
 
3.01 
 
0.0082 
 
0.0606  ±  0.013
   
 
4.6 
 
0.0003 
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Second Thesis 
Abstract 
 
Platelet derived growth factors (PDGF) are one of the major abundant growth factors which 
control the proliferation, growth and division of many cells. The effects exerted by the PDGF 
isoforms are achieved by the binding to their structurally related tyrosine kinase receptors, 
PDGF receptor α and β, which become phosphorylated. The current hypothesis was that 
Protein Kinase C (PKC) is a point of signal integration for PDGF receptor recycling. In this 
study the G protein coupled cytokines fMLP and a LPA were investigated. fMLP was an un-
investigated cytokine, where this study showed it to potentiate and stimulate PDGF β 
receptor phosphorylation as well as  induce activation of PKC. Furthermore, the downstream 
effector molecule AKT was potentiated in response to PDGF β receptor phosphorylation. 
This is early data supporting the hypothesis that PKC is a point of signal integration for 
PDGF receptor recycling and that all signals which result in receptor recycling must activate 
PKC. Furthermore LPA has been previously shown to cause PDGF β receptor recycling and 
activation of PKC. This study re-confirmed these findings, however identified that 
downstream effector molecules AKT, ERK 1 and 2 are not potentiated in response, 
nonetheless this requires further investigation.  
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1. Introduction 
1.1Background  
The research into growth factors (GFs) is of great importance as they play significant roles in 
the development of numerous cancers (Goustin et al., 1986). GFs are generally classified as 
polypeptides which bind to a high affinity cell membrane receptor, resulting in the 
stimulation of cell proliferation and/or differentiation (Goustin et al., 1986). Furthermore, 
GFs are exceptionally versatile; stimulating cell proliferation and/or differentiation in a vast 
number of diverse cell types, however some GFs are specific and thus stimulate only a 
particular cell type (King., 2012). The signalling pathways which under normal cellular 
conditions mediate the GFs are enhanced in cancer and the mitogenic signalling is affected by 
the oncogenes involved (Aaronson., 1991). 
There is on average an estimated figure of 267 individuals per 100,000 diagnosed with cancer 
in the U.K alone, placing it in the 22nd position for the world’s leading cancer rates (wcrfi., 
2011). These figures have continued to increase significantly, with a reported death of 7.6 
million individuals in 2008; stressing the need for a therapeutic intervention and highlighting 
the importance of research within this field (WHO., 2008).   
1.2 Platelet derived growth factors and tyrosine kinase receptor 
Platelet derived growth factor (PDGF) in particular are one of the major abundant GFs which 
control the proliferation, growth and division of many cells (Deuel & Huang., 1984). PDGF’s 
were initially discovered during the investigation into lesions of atherosclerosis, which 
identified activated platelets releasing a growth promoting activity (Kohler & Lipton., 1974; 
Ross et al., 1974).   PDGF’s are major mitogens for connective tissue types such as smooth 
muscle cells and fibroblasts, as well as controlling significant embryonic developments (Shim 
et al., 2010; Goustin et al., 1986). The signalling network of the platelet derived growth 
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factor is similar in both mice and humans as it includes four ligands, which are A, B, C and 
D. PDGF is a dimeric glycoprotein, made up of polypeptide chains, and thus the ligands 
forms disulphide linked homo/hetrodimers; however among these, only the A and B ligands 
are capable of forming biologically active and functional dimers, with their related tyrosine 
kinase receptors (figure 1.2.1) (Shim et al., 2010 ; Wu et al., 2008; Heldin & Westermark., 
1999; Karlsson., 2009). The PDGF isoforms, A and B polypeptide chains, are initially 
synthesized in a precursor form (immature), which will then be subjected to proteolytic 
processing (NH2 terminal for A-polypeptide chains and COOH for the B-polypeptide chain) 
to produce the mature form of the PDGF isoform. These can be observed on simple Sodium 
dodecyl sulfate gels, which will illustrate the migration of the mature form of PDGF at 30 
kDa in comparison to the immature reduced chains at 15 kDa (Heldin & Westermark., 1999). 
The mature A and B polypeptide chains are 100 amino acids in length and have 8 cysteine 
residues which are conserved, as two of the cysteine residues form key bonds in the dimer 
(2nd and 4th). However the remaining 6 residues are involved in intra-chain disulfide bonding 
(Heldin & Westermark., 1999). Furthermore, the A polypeptide chain is coded for by the 
gene on chromosome 7 and the B polypeptide chain gene is on chromosome 22, with both 
containing 7 exons. The exon function on both genes is highly similar as the first exon 
encodes the signal sequence, followed by the 2nd and 3rd exons, which are eventually removed 
as they both encode for the precursor sequence of the PDGF isoform. Subsequently exons 4 
and 5 then contain the encoding for the mature PDGF protein, ending then with exon 7 which 
is non coding. Exon 6 differs in the two gene; in the B-polypeptide chain, this may be 
removed as proteolytic maturation occurs, whereas in the A polypeptide chain there are two 
splice forms, one which contain the exon 6 and the other where it has been spliced out 
(Heldin & Westermark., 1999). 
98 
 
The effects exerted by the PDGF isoforms are achieved by the binding to the structurally 
related tyrosine kinase receptors which are PDGF Receptor α and β (Hooshmand-Rad et al., 
1998). Binding to the PDGF α receptor (thus dimerizing + phosphorylating) controls the 
development of vital organs such as the skin, kidneys and lungs among others. In addition the 
activated PDGF β receptor is significantly involved in early heamopoiesis and angiogenesis 
(Shim et al., 2010). The α receptor is able to form bonds with both the A and B polypeptide 
chains of the PDGF, however the β receptor bonds only to the B polypeptide chain (Andrae et 
al., 2008 ; Hooshmand-Rad et al., 1998) (Figure 1.2.1). Furthermore, both receptors are 
expressed on cell surfaces of glia cells fibroblasts, capillary endothelial cells, neuronal cells 
and other cells of mesenchymal origins (Hooshmand-Rad et al., 1998). The molecular size of 
the PDGF α receptor is slightly lower (170 kDa) than the PDGF β receptor (180 kDa), as well 
as each receptor consisting of an intracellular, transmembrane and extracellular domains 
(Shim et al., 2010; Heldin & Westermark, 1999). The extracellular division of both receptors 
consists of 5 domains which have a structure similar to immunoglobulins (D1-D5); this is 
linked to the intracellular part of the receptor through the transmembrane spanning region 
which leads to the split tyrosine kinase domain (Lokker et al., 1997 ; Heldin & Westermark., 
1999) 
Due to the significant effects the activated tyrosine kinase receptors have, an over stimulation 
results in tumour growth via the malignant cells, as these are then stimulated through the 
autocrine pathway. In addition PDGF is one of the many endogenous stimulators of 
angiogenesis which activates the cascade resulting in the formation of new blood vessels; 
angiogensis within the tumour occurs in the case of over stimulated PDGF receptors (Shim et 
al., 2010 ; Wu et al., 2008).  Furthermore, the increased activation of the tyrosine kinase 
receptors (PDGFRα or PDGFRβ) has also been observed in myeloid malignancies, lung 
cancers, gastrointestinal tumours, dermatofibrosarcoma protruberans to name a few, in 
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addition to many other tumours such as malignant gliomas (Shim et al., 2010 ; Wu et al., 
2008). Therefore an abnormal increase in activated PDGF receptor stimulation results in an 
enhanced signalling cascade highlighting it to be a key characteristic in a vast number of 
diseases and consequently becoming a target to exploit for the use of novel anti cancer drug 
development and therapeutic treatment (Shim et al., 2010 ; Wu et al., 2008; Östman et al ., 
2006) 
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Figure 1.2.1:  A schematic diagram of the PDGF isoforms and the binding to their 
corresponding tyrosine kinase receptors (PDGFRα or PDGFR β (Karlsson., 2009). 
The PDGF isoforms bind the PDGFR with different affinities, forming the corresponding 
hetro/homdimers, complexed to their receptor. The PDGF homodimers (AA and CC) can 
only bind the PDGF α receptor. The PDGF hetrodimer (AB) can bind both the α and the β 
receptors. The PDGF homodimer (DD) can only bind the β receptor, finally the homodimer 
PDGF BB is the only isoform which can bind both receptors (Heldin & Westermark., 1999; 
Lokker et al., 1997 ; Karlsson., 2009 ; Andrae et al., 2008). 
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Generally once the PDGF ligand binds the PDGF β receptor it is internalized and endocytosis 
occurs as it is compartmentalized into clathrin coated vesicles. The vesicles then shed the 
clathrin coat resulting in the formation of early endosomes as the internalized vesicles fuse 
(van der sluis et al., 2000). At this point the receptor is either degraded through lysosomal 
degradation via multivesicular bodies; a process which sorts the early endosomes into the late 
endosomal degradation pathway, or recycled back to the plasma membrane, for which Rab4a 
is a necessary protein (figure 1.2.2). The great family of monomeric GTPases, also known as 
Rab proteins, regulate important processes in the majority of vesicular sorting. In particular 
Rab4a is a central component of the recycling pathway, where it regulates the receptor 
recycling from early endosomes. Finally, the recycling of the PDGF β receptor back to the 
cell surface through Rab4a dependent recycling increases PDGF receptor activation (Hellberg 
et al., 2009; Karlsson et al., 2006). 
 
 
 
 
 
 
 
 
Figure1.2.2: The endocytic recycling and degradation processes of PDGF β receptor 
(Karlsson., 2009) 
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1.3 Intracellular signal transduction 
The intracellular signalling cascade of the PDGF β receptor requires a vast and significant 
number of phosphorylation processes which are stabilised through protein kinases and 
phosphatases. However signal transduction occurs through signalling molecules which are 
employed to the receptor once it has been activated; through the use of the specific domains 
on the signalling molecules, interaction with the receptor is enabled (Heldin & Westermark., 
1999). The binding of the PDGF ligand to its related tyrosine kinase receptor results in the 
dimerization and autophosphorylation of the PDGF receptor, which controls two significant 
functions depending on the tyrosine residues which are, phosphorylated (Heldin & 
Westermark, 1999). The phosphorylation of the conserved tyrosine kinase domains, tyrosine 
849 PDGFRα and Tyrosine 857 PDGFRβ, results in an increased catalytic kinase, in 
comparison to the residues external of the conserved domains causing the transduction of 
molecules containing Src homology domains, via the formation of docking sites (Heldin & 
Westermark., 1999). 
1.4 Src Homologies SH2 & SH3 
The majority of signalling molecules use the specific domain SH2 to interact and bind to the 
phosphorylated PDGF receptor as it binds phosphotyrosines. The Src family consists of many 
tyrosine kinases which have a SH2 domains present in the catalytic segment as well as being 
activated via either binding to the autophosphorylated PDGF receptor or dephosphorylation 
of the receptor. In general it is an important domain which is involved in the mitogenic 
response of PDGF (Heldin & Westermark., 1999). 
The SH3 domain is also present on the catalytic segment of many tyrosine kinases in the Src 
family and thus binds phosphorylated PDGFR, but it also distinguishes proline rich regions 
and the PDZ for the recognition of valine residues in the C terminal (Pawson & Scott., 1997) 
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Furthermore other transduction molecules which bind to the phosphorylated PDGFR include; 
PLCɣ, PI3 kinase, Src, SHP-2 and RasGAP (Heldin & Westermark, 1999; Karlsson, 2009). 
In addition there are the adaptor molecules including Grb2, Shc, Nck, Grb7 and Crk; finally 
there is the family of stat molecules (Heldin & Westermark, 1999). 
1.5 Stimulation of cell growth, differentiation, migration and prevention of 
apoptosis 
The activation of transduction molecules results in the stimulation of fundamental processes 
within the cells. 
1.5.1 Phospholipase- C (PLCɣ) 
 
PLCɣ cleaves phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] into an inositol 1,4,5-
trisphosphate and diacylglycerol, which causes an increased level of intracellular Ca2+ , 
which are mobilized.  The change in intracellular Ca2+ levels causes the stimulation and 
activation of classic protein kinases ɣ, α, and β; these result in cell growth and migration 
(Heldin & Westermark., 1999). Furthermore, the PLCɣ is phosphorylated through binding to 
the PDGFR which causes increased catalytic activity of the transduction molecule as specific 
residues are phosphorylated (Heldin & Westermark., 1999). In addition, full activation of 
PLCɣ is dependent on PI3 Kinase (Heldin & Westermark., 1999). 
1.5.2 Protein Kinase C (PKC) 
 
PKC is a family of protein kinases, which are involved in the signal transduction cascade 
downstream of the PDGF β receptor. As mentioned before hand, activation of PKC occurs as 
the levels of diacylglycerol and intracellular Ca2+ increases. In particular the activation of 
PKC α is a critical step for the recycling of the PDGF β receptor as it promotes receptor 
recycling from early endosomes (Hellberg et al., 2009; Karlsson et al., 2006). 
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1.5.3 Phosphatidylinositol 3 Kinase (PI3 K) 
 
The family of PI3 kinases consists of several members, however the ones that are activated 
by the PDGFR, or other tyrosine kinase receptors, contain a catalytic subunit (p110) and a 
regulatory subunit (p85). In comparison to the PLCɣ molecule, PI3 kinase phosphorylates the 
[PI(4,5)P2] into phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3] (Heldin & 
Westermark., 1999). The PI3 K has a significant function as it generates the phospholipid 
PIP3 second messenger which binds AKT (protein kinase B) on the pleckstrin homology and 
activates AKT, a downstream effector molecule, through phosphorylation. This results in 
stimulation of cell growth and prevention of apoptosis. Other biological responses exerted by 
the activated PI3K include actin reorganization and chemotaxis (Heldin & Westermark., 
1999).  
1.5.4 Mitogen activated protein kinase ( Ras-MAPK) 
 
This pathway leads to the activation of important downstream effector molecules, activating 
the MAPK pathways, which stimulate cell growth, differentiation and migration (Heldin & 
Westermark., 1999; Andrae et al., 2008). These processes occur as Grb2 (an adaptor 
molecule) binds Sos1, a guanine nucleotide exchange factor (GEF) site, through its SH3 
domain resulting in the activation of Ras. This process occurs as the GEF allows the release 
of guanosine diphosphate from the Ras GDP and enables the binding of guanosine 
triphosphate forming the activated Ras GTP. Finally the activated Ras GTP activates RaF-1 
initiating the Mitogen activated protein kinase cascade (MAPK) (Heldin & Westermark., 
1999; Andrae et al., 2008). 
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1.6 Receptor regulation 
1.6.1 Protein Tyrosine Phosphatase (PTP) 
 
Protein tyrosine phosphatases are a family of enzymes, which regulate important cellular 
processes such as cell growth, differentiation and oncogenic transformations via the removal 
of phosphate groups from phosphorylated proteins (figure 1.6.1a)  (Fischer et al., 1991). 
Recent research has shown that PTP’s regulate receptor recycling of the PDGF β receptor via 
the dephosphorylation of this receptor; the loss of PTP resulted in the hyperphosphorylation 
of the receptor at position Y1021. In addition, recycling of PDGF β receptor to the cell 
surface was found to be reliant on Rab4a dependent recycling, as well as that PKC α being a 
critical signalling kinase regulating the Rab4a dependent recycling of the PDGF receptor 
(Hellberg et al., 2009; Karlsson et al., 2006). 
 
 
 
 
 
 
 
Figure 1.6.1a: The de/phosphorylation process of proteins regulated by PKC and PTP. 
(Karlsson et al., 2009). 
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1.7 Cytokine-induced potentiation of PDGF receptor signalling 
Previously established findings on Cytokine induced potentiation of PDGF β receptor 
signalling: 
The use of the G protein coupled cytokine lysophosphatidic acid (LPA) , has proved to 
increase PDGF β receptor phosphorylation as it activates PKC which in turn activates PDGF 
β receptor recycling (Hellberg et al., 2009; Karlsson et al., 2006).  Furthermore, it has been 
hypothesised that PKC is a  point of signal integration for PDGF β receptor. 
1.7.1 Lysophosphatidic acid (LPA) 
 
The phospholipd LPA is a cytokine which acts as a signalling molecule and binds to its 
lysophospholipid receptor, a G protein coupled receptors. Once bound to its receptor and 
activated, depending on the cell type, a variety of effects are exerted within the cell.  LPA 
activates PKC and therefore results in an increase of receptor recycling leading to an increase 
in activated PDGF β receptor; calcium levels are mobilized as it is released from the 
endoplasmic recticulum, via phospholipase-mediated inositol 1,4,5-trisphosphate and 
diacylglycerol (Yuan et al., 2002). In addition downstream receptor activation by LPA 
activates Ras and Rho. Rho is a downstream signalling GTPase molecule of PI3 K and thus 
leads to similar effects as the AKT/PKB; Ras activates the MAPK/ERK pathway (Yuan et 
al., 2002). 
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Figure 1.7.1: Activated downstream effector molecules by LPA (Heldin et al., 1998) 
 
1.7.2 N-Formylmethionyl-leucyl-phenylalanine (fMLP) 
 
N-Formylmethionyl-leucyl-phenylalanine (fMLP) is a strong chemo-attractant, more 
specifically for polymorphonuclear neutrophils, by binding to their specific N-formyl peptide 
receptors (FPR) which are seven rhodopsin like helical transmembrane G protein coupled 
receptors of the cells (Murphy, 1994). In neutrophils, early work has proved that this cytokine 
induces activation of phospholipase C β , which  in turn results in the generation of inositol 
1,4,5-trisphosphate and diacylglycerol; PKC activation (Ding and  Badweyt, 1993). 
Furthermore, many researchers have proved that fMLP stimulates tyrosine phosphorylation in 
the MAPK family and extracellular signal regulated kinases (ERK) in neutrophils (Kusunoki 
et al., 1992; Torres et al .,1993; Grinstein & Furuya, 1992; Rollet et al .,1994).  However 
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fMLP induced phosphorylation of the PDGF β receptor is still unknown. Although the 
neutrophil cells used in previous studies employed transfection of cells with the FPR 
receptor, similar results may be expected for the PDGF β receptor (Kusunoki et al., 1992; 
Torres et al .,1993; Grinstein & Furuya, 1992; Rollet et al .,1994). 
 
1.8 Benefits of project 
 
The investigation of the projects allows more knowledge to be gained on downstream 
effector molecules of PDGF β receptor and a greater understanding of intercellular signalling 
mediated by the receptor phosphorylation. Also investigating the effects of the cytokines on 
PDGF receptor phosphorylation allows a greater understanding of how cytokines potentiate 
the signal and whether it is through the established receptor recycling pathway or perhaps 
other unexplored possibilities. Finally the findings will provide valuable findings on the early 
hypothesis that PKC is a point of signal integration for PDGF receptor recycling.  
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1.9 Summary of project aims and objectives  
 
The research project was separated into two sections: 
1. The first part of the project investigated whether fMLP potentiates the ability of the 
PDGF-BB ligand to phosphorylate the PDGF β receptor and whether all downstream 
signalling effector molecules were affected. 
 
2. The second part of the project expanded on the findings of LPA, therefore whether the 
phosphorylation of all downstream signalling effector molecules of PDGF β receptor are 
potentiated.  
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2. Materials and Method 
2.1 Reagents 
Lysophosphatidic acid (LPA) and fMLP (N-formyl-methionine-leucine-phenylalanine) were 
purchased from Sigma-Aldrich. The primary antibodies MARCKS, P-TYR, PERK  and the 
PDGF-BB ligand were all purchased from Santa Cruz Biotechnology. The primary antibodies 
CTB, PMARCKS, AKT, PAKT and ERK were all purchased from Cell signalling 
technologies. The HRP Goat-anti-mouse and anti-rabbit IgG were both purchased from 
Invitrogen. Dulbecco's Modified Eagle's Medium purchased from Lonza Bio-Whittaker and 
Fetal bovine serum from BioSera. Lysis buffer make, 2 x loading sample buffer, Tween 20, 
NaOH, Wheat Germ Agglutinin beads, Penicillin and Streptomycine were purchased from 
Sigma Aldrich. Finally Coomassie plus protein assay reagent was fromThermo Scientific. 
2.2 PDGF β receptor phosphorylation and Downstream signalling 
molecules 
The project employed the use of PDGF-BB as a ligand to simulate the receptors as this is the 
only isoform which can bind both receptors (Heldin & Westermark., 1999; Lokker et al., 
1997). In addition wild type mouse embryonic fibroblast (MEF) cells were used from 
littermate wild type mice according to the protocol described previously in the paper You-Ten 
et al 1997. 
There are several downstream signalling molecules of PDGF β receptor phosphorylation 
which were investigated in order to determine whether the effect of the cytokines 
subsequently affected the phosphorylation of the downstream effector molecules. 
The monoclonal mouse antibodies to phosphotyrosine P-Tyr (py99) was employed to detect 
total tyrosine phosphorylation of the PDGF receptor as this antibody binds phosphotyrosine 
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residues located within the receptor cytoplasmic domains. Furthermore, C terminal β 
antibody was used as to specifically bind the PDGF β receptor and measures the 
phosphorylation of this receptor. 
The phosphorylation of downstream effector molecules which were investigated are 
MARCKS, AKT, ERK 1 and ERK 2. 
2.3 Cell Culturing 
Wild type mouse embryonic fibroblast (MEF) cells were derived from littermate wild type 
mice described previously in the paper You-Ten et al 1997 and were a gift from Canada 
Institute of Health and Research. The cells were grown in Dulbecco's Modified Eagle's 
Medium (Lonza Bio-Whittaker) containing 10% Fetal bovine serum (BioSera) and 1% 
Penicillin and Streptomycine (Sigma Aldrich). 
2.4 MEF cell stimulation and lysis  
The cells were split into thirteen T 253 cell culture flask (Cell Star Greiner Bio-One) and 
starved overnight in Dulbecco's Modified Eagle's Medium only (Lonza Bio-Whittaker). One 
flask was unstimulated; four flasks were stimulated with 5 ng/ml PDGF-BB ligand, the 
following four with 10 µM LPA or 100 nM fMLP and the final four with both 5 ng/ml 
PDGF-BB and 10 µM LPA or100 nM fMLP. Each batch of cells was stimulated for 10, 20, 
40 and 60 minutes in 370C incubators. The stimulation was stopped by placing the T 253 
flasks on ice and finally rinsing twice with ice cold Phosphate buffered saline (PBS). 
Subsequently the cells were lysed in150 µl of lysis buffer for 15 minutes, which consisted of; 
0.5% Trition X-100, 0.5% deoxycholic acid, 150 mM NaCl, 20 mM Tris (pH 7.5), 10 mM 
EDTA, 0.5 mM Na3VO4 and 1 mg/ml aprotinin (Sigma Aldrich). The lysates were cleared 
via centrifugation (Biofuge Heraeus Sepatech) for 15 minute at 13,000 rpm in 40C.  For the 
total cell lysate samples, 40 µl was removed and added to the same volume of 2 x loading 
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sample buffer (4% SDS, 20% Glycerol, 0.12M Tris pH 6.8, and 10% BME, all from Sigma 
Aldrich), which was heated for 5 minutes at 950C. 
2.5 Immunoprecipitation (IP) 
The immunoprecipitation of the PDGF receptors was conducted by mixing equal amounts of 
the proteins with lysis buffer, making it up to a 1 ml volume. This was determined via a 
protein assay which measured (Softmax Molecular Devices-Precision Microplate reader) the 
optical density of 5 µl of the total cell lysate sample mixed with 200 µl Coomassie plus 
protein assay reagent (Thermo Scientific). 
Approximately 5 µg/ml of CTβ antibody was added to the mixture and incubated end over 
end overnight at 40C.  Then 30 µl of protein A beads was added and incubated end over end 
for 1 hour at 40C. Subsequently the beads were washed  3 x by adding 1 ml of lysis buffer, re-
suspending the beads and then using a magnetic strip to separate the beads from the lysis 
buffer. On the last wash the lysis buffer is removed, leaving the beads, and 30 µl of the 2 x 
sample loading buffer was added. The samples were heated for 5 minutes at 950C.  
2.6 WGA bound PDGF receptor 
A volume of 40 µl of WGA (wheat germ agglutinin from Sigma Aldrich) beads was added to 
the mixture and was incubated end over end for 1 hour at 40C . The beads were washed 3 x 
by adding 1 ml of lysis buffer, re-suspending the beads, and centrifuging for 3 minutes at 
13,000 rpm (Biofuge Heraeus Sepatech). On the last wash the lysis buffer is removed, 
leaving the beads, and 40 µl of the 2 x sample loading buffer was added. The samples were 
heated for 5 minutes at 950C.  
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2.7 SDS-PAGE, Western Blot and membrane development 
 
The samples were separated using SDS-PAGE (Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis) according to the Laemmli Protocol 1970 (Bio Rad multicasting Kit). The 
gels were either 7%, for PDGF receptor, MARCKS and AKT detection and 10% for ERK 
detection. Finally they were transferred onto a nitrocellulose membrane (Transblot Turbo 
Transfer Pack BioRad).  
The membrane was blocked using PBS containing 5 % Fetal bovine serum (BioSera) for 1 
hour and incubated overnight with the primary antibody made up according to manufacturers 
protocol. Following the membrane was washed 6 x for 5 min each, using PBS containing 
0.01% Tween 20 (Sigma Aldrich) and incubated for 1 hour with the secondary antibody 
followed by the same procedure of membrane washing. Finally, the bound antibodies were 
visualized and quantified via enhanced chemiluminescence using ECL reagents 1 and 2 
(Gene Flow LTD) the softwares GeneSnap and GeneTools on the UV Transilluminator 
Syngene from Gene Flow. 
2.8 Membrane stripping and re-blotting 
Once the membrane had been developed it was incubated with 0.4 M NaOH (Sigma Aldrich) 
for 10 minutes and subsequently washed for 5 minutes (6 x) with PBS containing 0.01% 
Tween 20. It was then re-blocked using PBS containing 5 % Fetal bovine serum (BioSera) 
and the following primary antibody is re-probed. 
2.9 Blotting of primary and secondary antibodies 
Depending on which receptor signal being investigated, different antibodies were used and 
made up according to the manufacturer’s protocol: 
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▪ P-Tyr (mouse source - Santa Cruz Biotechnology) primary antibody for detecting tyrosine 
phosphorylation of proteins containing tyrosine. Secondary antibody is HRP Goat-anti-mouse 
IgG H + L (Invitrogen). 
▪ C Terminal antibody (rabbit source- home made) primary antibody specific for PDGF β 
receptor phosphorylation. Secondary antibody is HRP Goat-anti-rabbit IgG OS GRD 
(Invitrogen). 
▪ MARCKS (mouse source -Santa Cruz Biotechnology) primary antibody for MARCKS 
protein. Secondary antibody is HRP Goat-anti-mouse IgG H + L (Invitrogen). 
▪ PMARCKS (rabbit source- Cell signalling technology) primary antibody for detecting 
phosphorylated MARCKS protein. Secondary antibody is HRP Goat-anti-rabbit IgG OS 
GRD (Invitrogen). 
▪ ERK (rabbit source- Cell signalling technology) primary antibody for ERK protein. . 
Secondary antibody is HRP Goat-anti-rabbit IgG OS GRD (Invitrogen). 
▪ PERK (rabbit source- Santa Cruz Biotechnology) primary antibody for detecting 
phosphorylated ERK protein. Secondary antibody is HRP Goat-anti-rabbit IgG OS GRD 
(Invitrogen). 
▪ AKT (rabbit source -Cell signalling technology) primary antibody for AKT protein. 
Secondary antibody is HRP Goat-anti-rabbit IgG OS GRD (Invitrogen). 
▪ PAKT (rabbit source- Cell signalling technology) primary antibody for the detection of 
phosphorylated AKT protein. Secondary antibody is HRP Goat-anti-rabbit IgG OS GRD 
(Invitrogen). 
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3. Results 
3.1 fMLP stimulation of PDGF receptor phosphorylation 
The effects of the cytokine fMLP on the PDGF β receptor was determined by stimulating the 
mouse embryonic fibroblast cells in 13 T 253 cell culture flask; four flasks with 5 ng/ml 
PDGF-BB, the following four with 100 nM fMLP and the final four with the two combined; 
the last remaining flask was unstimulated. For each batch of the cells, a stimulation period of 
10, 20, 40 and 60 minutes was conducted. The total cell lysates (TCL) were boiled in 2 x 
sample loading buffer and separated on SDS-PAGE gels; subsequently followed by a 
Western blot. The membranes were immunoblotted with P-Tyr to detect total tyrosine 
phosphorylation and then stripped and re-probed with PDGF β receptor antibody (CTB). 
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3.1.1 Total cell lysate samples stimulated with fMLP 
 
The fMLP stimulated as well as potentiated tyrosine phosphorylation of the PDGF β receptor. 
There was a pattern on the western blot results which illustrated that the combination of 
fMLP with the PDGF-BB ligand increased the ligands ability to phosphorylate the PDGF 
receptor (figure 3.1.1a).  However in order to analyse the data accurately the bands observed 
on the Western blot were quantified using the software GeneTools (figures 3.1.1b/c). 
p-Tyr 
Immunoblot 
Stripped and re-probed 
with CTB Immunoblot 
Figure 3.1.1a: Western Blot of PDGF receptor phosphorylation at 190 kDa stimulated with 
fMLP and PDGF-BB 
 
p-Tyr  
Immunoblot  
Stripped and 
 re-probed with 
CTB 
Immunoblot 
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Quantified p-Tyr Blot for total tyrosine phosphorylation of the PDGF receptor in the 
total cell lysate  
 
There was a clear high level of background banding in the unstimulated sample.  Throughout 
the stimulation time points, the samples containing both the fMLP and PDGF-BB illustrated 
increased levels of phosphorylation in comparison to PDGF-BB and fMLP stimulations 
alone. In comparison at 10 minutes, there was a high level of phosphorylation for stimulation 
with PDGF-BB, which decreased as the stimulation time increased. There is a strange pattern 
in the PDGF-BB stimulations as the phosphorylation increased again after 20 minutes 
stimulation. However at 10 minutes stimulation with fMLP there were low levels of 
phosphorylation, but these significantly increased as the stimulation time prolonged and 
remained fairly constant at 60 minutes stimulation. 
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Figure 3.1.1b: PDGF receptor tyrosine phosphorylation in response to stimulation with fMLP and 
PDGF-BB 
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The membrane was stripped and re-probed with PDGF β Receptor antibody  
Again there was a clear high level of background banding in the unstimulated sample. The 
fMLP and PDGF-BB combined stimulation was increased significantly at 10 minute 
stimulation, however as the time prolonged, the phosphorylation decreased after 20 minutes. 
PDGF-BB stimulation alone increases the phosphorylation at 20-40 minutes and then 
decreases after 40 minutes. The same pattern was observed for fMLP stimulation. 
 
 
Figure 3.1.1c: Phosphorylation of PDGF β receptor in response to stimulation with fMLP and 
PDGF-BB 
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3.2 WGA bound PDGF receptor phosphorylation 
 
Due to the high levels of background banding, other proteins that are phosphorylated are also 
detected on the membrane as the total cell lysate samples were used, therefore the results for 
this would be inaccurate.  In order to solve this problem an Immunoprecipitation was 
conducted to precipitate out the PDGF receptor. This employed 5 µg/ml of CTB antibody to 
bind the PDGF receptor in the total cell lysate and protein A beads to bind the complex. 
However this method failed as the PDGF receptor could not be precipitated out and detected 
at 190 kDa on the western blot (figure 3.2.1).  
 
 
 
 
 
 
 
 
 
Figure 3.2.1: No signal detection for PDGF receptor immunoprecipitation. 
The membrane was blotted with PDGF β Receptor antibody; however there is no signal 
detected at 190 kDa. There are clear antibody bands (IgG) at 55 kDa 
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Following the failure of the immunoprecipitation method, WGA beads were employed to 
precipitate the PDGF receptor out of the total cell lysate samples. The WGA beads were 
added and bound all glycosylated proteins, namely the PDGF receptor. This method was 
successful and the background banding was reduced significantly (figure 3.2.2). Furthermore, 
the bands observed on the membrane for the samples with WGA beads were not as clear and 
clean as those on the TCL. This method still requires further optimization in order to obtain 
clearer and cleaner membranes, nonetheless the results presented that fMLP does indeed 
potentiate PDGF-BB ligands ability to phosphorylate the PDGF receptor. 
Furthermore, the results observed for the WGA bound PDGF receptor on the p-Tyr and CTB 
blots both illustrate the increase in PDGF receptor phosphorylation as fMLP and PDGF-BB 
ligand are combined (figures 3.2.2). However to obtain accurate results, the bands observed 
on the western blots were quantified using the software GeneTools (3.2.3/4). 
 
 
.  
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Figure 3.2.2: Western Blot of WGA bound PDGF receptor phosphorylation at 190 kDa 
stimulated with fMLP and PDGF-BB 
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The background banding in the unstimulated sample was reduced significantly. The 
stimulation with PDGF-BB and fMLP combined resulted in the highest level of 
phosphorylation. This was followed by the samples stimulated with fMLP alone and finally 
those stimulated with PDGF-BB. All samples showed a period of phosphorylation followed 
by dephosphorylation. Samples which were stimulated with fMLP maintained a longer period 
of phosphorylation. 
 
 
 
Figure 3.2.3: Phosphorylation of WGA bound PDGF receptor in response to stimulation 
with fMLP and PDGF-BB 
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Quantified CTB Blot for phosphorylation of the WGA bound PDGF β receptor  
The membrane was stripped and re-probed with PDGF β Receptor antibody  
Again the background banding was reduced significantly. The result is very clear as the 
PDGF β receptor is phosphorylated the most once fMLP and PDGF-BB are combined. This 
is followed by fMLP stimulation alone and finally the PDGF-BB ligand.  A period of de-
phosphorylation follows for all stimulations after 20 minutes. These results indicate that not 
only does fMLP increase PDGF receptor phosphorylation; it can still do so in the absence of 
the PDGF-BB ligand, hence fMLP stimulation results in higher phosphorylation than PDGF-
BB ligand alone. 
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Figure 3.2.4: Phosphorylation of WGA bound PDGF β receptor in response to stimulation 
with fMLP and PDGF-BB 
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3.3 Downstream signalling effector molecules phosphorylation by fMLP  
The signalling molecules downstream of the PDGF β receptor, which were investigated, were 
MARCKS and AKT (Protein kinase B). The phosphorylation was determined by separating 
the Total cell lysate samples by SDS-PAGE followed by western blot to transfer the samples 
onto a nitrocellulose membrane. This was immunoblotted with the phosphorylated protein 
antibody, and then the membrane was stripped and re-probed with the protein antibody. 
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3.3.1 The effect of fMLP on MARCKS  phosphorylation 
 
The phosphorylation of MARCKS (Myristoylated alanine-rich C-kinase substrate), a major 
substrate for protein kinase C, was investigated in order to assess if protein kinase c was 
activated in response to PDGF β receptor stimulation. Once the TCL samples were separated 
out and transferred onto the nitrocellulose membrane, it was immunoblotted with PMARCKS 
(phosphorylated MARCKS antibody) followed by stripping and re-probing with MARCKS 
protein antibody. Furthermore, the results observed for the PMARCKS blot illustrated the 
increase in  phosphorylation as fMLP and PDGF-BB ligand are combined (figures 3.3.1a). 
However to obtain accurate results, the bands observed on the western blots were quantified 
using the software GeneTools (3.3.1b/c). 
 
Figure 3.3.1a: Western Blot of MARCKS phosphorylation at 75 kDa stimulated with fMLP 
and PDGF-BB 
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MARCKS phosphorylation and total MARCKS protein available 
In both figures, the combination of fMLP with the PDGF-BB ligand resulted in the highest 
level of MARCKS phosphorylation as well as in the amount of MARCKS protein available 
(3.3.1b/c). 
There was a clear difference observed once the stimulation had begun in comparison to the 
unstimulated samples, therefore validating the results.  Furthermore the lowest levels of 
protein available as well as phosphorylated protein were in the samples which were 
stimulated with PDGF-BB ligand alone. At 20 minutes, stimulation with fMLP alone and that 
combined with the PDGF-BB ligand were very similar, however the combined stimulation 
de-phosphorylates slightly faster. Finally for the PDGF-BB ligand stimulation, there is a 
slight (yet insignificant in comparison to the other two) increase at 40-60 minutes. 
Therefore fMLP stimulation alone already increases levels of MARCKS phosphorylation 
(and thus PKC activity) as well as in addition to PDGF-BB ligand. 
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Figure 3.3.1b: Phosphorylation of MARCKS in response to stimulations with PDGF-BB and fMLP 
 
Figure 3.3.1c: Total MARCKS protein available in response to stimulations with PDGF-BB and 
fMLP 
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3.3.2 The effect of fMLP on AKT (protein kinase B) phosphorylation 
 
The TCL samples were separated out and transferred onto the nitrocellulose membrane, 
which was then immunoblotted with PAKT (phosphorylated AKT antibody) followed by 
stripping and re-probing with AKT protein antibody. Furthermore, the results observed for 
the AKT blot illustrated the increase in phosphorylation as fMLP and PDGF-BB ligand are 
combined, however stimulation with PDGF-BB ligand alone also results in a high level of 
AKT phosphorylation (figures 3.3.2a). Furthermore in order to obtain accurate results, the 
bands observed on the western blots were quantified using the software GeneTools (3.3.2b/c). 
 
 
 
 
 
 
Figure 3.3.2a: Western Blot of AKT phosphorylation at 60 kDa stimulated with fMLP and 
PDGF-BB 
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AKT phosphorylation and total AKT protein available 
The level of phosphorylation in the unstimulated sample is very low in all 3 stimulations 
(figure 3.3.2b), although there is a high level of protein available (figure 3.3.2c). At 10 
minutes, the stimulation with combined fMLP and PDGF-BB has the highest 
phosphorylation, followed by PDGF-BB alone and finally fMLP. Comparing this to figure 
3.3.6, the protein levels in the combination sample remain high, however those of PDGF-BB 
and fMLP alone decreases significantly, and continues to do so until 20 minutes. 
After 20 minutes, the period of phosphorylation ends for PDGF-BB and fMLP combined 
where it has reached a peak, and begins to undergo dephosphorylation and thus decrease. 
Nonetheless the protein levels still remain high but dip slightly at 40-60 minutes. 
After 10 minutes, the period of phosphorylation ends for PDGF-BB and fMLP stimulations 
alone, reaching a slight peak. However although it decreases, there are high protein levels 
available which continue to increase. This doesn’t seem to affect the phosphorylation as 
dephosphorylation has already begun. 
Therefore as fMLP is combined with the PDGF-BB ligand, higher levels of AKT 
phosphorylation are observed. 
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Figure 3.3.2b: Phosphorylation of AKT in response to stimulation with fMLP and PDGF-BB 
 
 
Figure 3.3.2c: Total AKT protein available in response to stimulation with fMLP and PDGF-BB 
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3.4 Expanding on previous findings of Lysophosphatidic acid (LPA) 
In order to expand on the previous established findings that LPA potentiates the ability of 
PDGF-BB to phosphorylate the PDGF receptors, a control experiment was conducted to 
assess this. Four T 253 cell culture flasks were stimulated with and without LPA in the 
following stimulation orders; all stimulations were for 5 minutes. 
1 ng/ml PDGF-BB 
1 ng/ml PDGF-BB + 10 µm LPA 
5 ng/ml PDGF-BB 
5 ng/ml PDGF-BB + 10 µm LPA 
20 ng/ml PDGF-BB 
The total cell lysate was separated out via SDS-PAGE and the samples transferred onto a 
nitrocellulose membrane for western blotting. Once visualized via enhanced 
chemiluminescence the results confirmed previously established findings (figure 3.4.1). 
Furthermore, to visualize this data clearly, the bands were quantified using the software 
GeneTools (figure 3.4.2) 
 
 
 
 
 
 
 
p-Tyr immunoblot 
 
 
Immunoblot  
Figure 3.4.1: Western blot of PDGF receptor phosphorylation at 190 kDa stimulated by PDGF-BB 
ligand and LPA 
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The ability of the PDGF-BB ligand to phosphorylate the phosphorylation of the PDGF 
receptor is clearly potentiated.  The combination of LPA induces a two fold increase in 
phosphorylation. Furthermore the addition of LPA produces phosphorylation results slightly 
higher than stimulation with even 20 ng/ml PDGF-BB ligand. Therefore previously 
established findings are re-confirmed. 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.2: Phosphorylation of the PDGF receptor in response to stimulation with PDGF-
BB and LPA
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3.5 Total PDGF receptor tyrosine phosphorylation & PDGF β receptor by 
stimulation with LPA 
 
Furthermore to further assess the effects of LPA on the PDGF receptors, stimulations over a 
period of an hour were assessed. The TCL were separated via SDS-PAGE and transferred 
onto a nitrocellulose membrane using western blotting. Once visualized via enhanced 
chemiluminescence (figure 3.5.1) the results were also quantified to assess the data more 
accurately (3.5.2/3). 
There is a high level of background banding in the unstimulated samples, as the total cell 
lysate were used. However the main pattern which can be detected from the western blot is 
that as time prolongs, the PDGF receptor phosphorylation decreases; finally in the samples 
which contain the combination of LPA and PDGF-BB this only seems to be increasing. 
Unfortunately the IP with CTB antibody for this did not work, neither did the WGA beads. 
 
 
 
 
 
 
 
 
 
Figure 3.5.1: Western blot of PDGF receptor phosphorylation at 190 kDa stimulated by 
PDGF-BB ligand and LPA 
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Quantification of p-Tyr and CTB immunoblots stimulated with PDGF-BB 
and LPA 
On figure 3.5.2 the clear background banding can be observed as a peak. 
p-Tyr immunoblot: 
If the unstimulated sample point were to be dis-regarded, the data shows positive results that 
LPA does induce and potentiate PDGF receptor phosphorylation. At ten minutes the highest 
phosphorylation is recorded for the sample containing the PDGF-BB alone, however this 
decreases almost immediately and dephosphorylation occurs. 
For the samples containing LPA alone and also the combination both illustrate low levels of 
phosphorylation initially at 10 minutes, but these increase immediately and continue to do so 
even at 60 minutes.  
CTB immunoblots: 
When observing the phosphorylation of the PDGF β receptor, lower levels of background 
banding is present in the unstimulated sample. At 10 minutes stimulation the phosphorylation 
of the sample containing both the LPA and PDGF-BB is fairly low but continues to increase, 
surpassing the other two stimulations and continues to have high levels of phosphorylation 
even at 60 minutes. LPA alone results in higher phosphorylation levels than PDGF-BB, 
however both increase then reach a peak at 20 minutes, after which they undergo de-
phosphorylation until 40 minutes, before slightly increasing again. 
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Figure 3.5.2: Phosphorylation of PDGF tyrosine receptor in response to stimulation by LPA and 
PDGF-BB 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.3: Phosphorylation of PDGF β receptor in response to stimulation with LPA and PDGF-BB 
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3.6 The effect of LPA on MARCKS phosphorylation 
 
The phosphorylation of MARCKS, a major substrate for protein kinase C, was investigated in 
order to assess if protein kinase c was activated in response to PDGF β receptor stimulation 
with LPA. Once the TCL samples were separated out and transferred onto the nitrocellulose 
membrane, it was immunoblotted with PMARCKS (phosphorylated MARCKS antibody) 
followed by stripping and re-probing with MARCKS protein antibody. Furthermore, there 
was a minor error made when stimulating the samples, resulting in the use of Dulbecco's 
Modified Eagle's Medium  containing 10% Fetal bovine serum and 1% Penicillin and 
Streptomycine for the stimulations. Therefore the stimulation medium contained growth 
factors which can increase and affect the levels of phosphorylation observed. 
The results observed for the P/MARCKS blot (figure 3.6.1) were difficult to interpret on the 
western blot and thus were quantified using the software GeneTools (figures 3.6.2/3). 
Figure 3.6.1: Western blot of MARCKS phosphorylation at 75 kDa stimulated by PDGF-BB 
ligand and LPA 
 
Figure 3.4.5: Phosphorylation of PDGF β receptor in response to 
stimulation by LPA and PDGF-BB 
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MARCKS phosphorylation and total MARCKS protein available 
During the first 10-20 minutes stimulations the combination of LPA with the PDGF-BB 
ligand has low levels of MARCKS phosphorylation. There are higher levels of MARCKS 
phosphorylation with fMLP and PDGF-BB lone stimulations (figure 3.6.2). This is translated 
in the level of MARCKS protein available as the sample with the combination has the lowest 
protein level. 
However after 20 minutes, there is a sudden increase in both the level of MARCKS protein 
available as well as the phosphorylation of it.  This exceeds both the level of MARCKS 
phosphorylation observed for the samples with the lone stimulations. Therefore the increase 
noted in MARCKS phosphorylation after combining LPA with PDGF-BB ligand requires a 
period of time, but it does activate MARCKS. 
Furthermore as noted beforehand, the addition of medium which contained growth factors 
could have had a significant effect on the results observed. Therefore a repeat is crucial. 
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Figure 3.6.2: Phosphorylation of MARCKS in response to stimulations with PDGF-BB and LPA 
 
 
 
 
 
 
 
 
 
Figure 3.6.3: Total MARCKS protein available in response to stimulations with PDGF-BB and LPA 
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3.7 The effect of LPA on AKT (protein kinase B) phosphorylation 
 
The TCL samples were separated out and transferred onto the nitrocellulose membrane, 
which was then immunoblotted with PAKT (phosphorylated AKT antibody) followed by 
stripping and re-probing with AKT protein antibody. Furthermore, there was a minor error 
made when stimulating the samples, resulting in the use of Dulbecco's Modified Eagle's 
Medium  containing 10% Fetal bovine serum and 1% Penicillin and Streptomycine for the 
stimulations. Therefore the stimulation medium contained growth factors which can increase 
and affect the levels of phosphorylation observed. It was difficult to analyse the western blot 
from the bands alone (figure 3.7.1) thus they were quantified using the software GeneTools 
(figure 3.7.2/3). 
 
Figure 3.7.1: Western Blot of AKT phosphorylation at 60 kDa stimulated with LPA and 
PDGF-BB 
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AKT phosphorylation and total AKT protein available 
The sample containing both LPA and PDGF-BB has the lowest level of phosphorylation. 
Initially at 10 minutes, the highest level of AKT phosphorylation is observed for the sample 
stimulated with PDGF-BB ligand alone. This then decreases almost immediately undergoing 
de-phosphorylation. However with the LPA lone stimulation the phosphorylation is slightly 
lower than PDGF-BB alone, also peaking at 10 minutes and then gradually decreasing. 
The levels of protein correspond to the level of phosphorylation.  Although due to the error of 
using medium which contained growth factors, the phosphorylation may be exaggerated, 
particularly within the sample stimulated with PDGF-BB ligand alone and thus preventing 
any noticeable change in phosphorylation. 
A repeat is crucial. 
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Figure 3.7.2: Phosphorylation of AKT in response to stimulation with LPA and PDGF-BB 
 
Figure 3.7.3: Total AKT protein available in response to stimulation with LPA and PDGF-
BB 
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3.8 The effect of LPA on ERK protein phosphorylation 
 
The last downstream effector molecule which was investigated for stimulations with LPA 
was the phosphorylation of ERK 1 at 44 kDa and ERK 2 at 42 kDa.  This stimulation also 
employed the error which used medium that contained growth factors for stimulation. The 
TCL samples were separated out and transferred onto the nitrocellulose membrane, which 
was then immunoblotted with PERK (phosphorylated ERK antibody) followed by stripping 
and re-probing with ERK protein antibody, which will both bind the two different proteins 
(figure 3.8.1). Again the bands were quantified as it was too difficult to assess the results 
otherwise (figures 3.8.2/3). 
 
ERK 1 Phosphorylation: 
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Figure 3.8.1: Western Blot of ERK 1 phosphorylation at 44 kDa stimulated with LPA 
and PDGF-BB 
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ERK 1 Phosphorylation 
 
ERK 1 phosphorylation is not increased by the combination of LPA with PDGF-BB.  
The highest level of phosphorylation is observed for the sample which was stimulated with 
the PDGF-BB ligand alone.  This is followed by the sample stimulated with LPA alone and 
finally that which was stimulated with the combination.  
However when observing the levels of ERK 1 protein available, the highest levels are 
observed for samples which had been stimulated with LPA. In comparison the lowest levels 
of ERK 1 protein is observed in the sample where only PDGF-BB has been used to 
stimulated.  
These results could indicate that all of the protein (or most of it) was phosphorylated with the 
stimulation of PDGF-BB, however this could be a major error due to the medium used. 
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Figure 3.8.2: Phosphorylation of ERK 1 in response to stimulation with LPA and PDGF-BB 
 
Figure 3.8.3: Total ERK 1 protein available in response to stimulation with LPA and PDGF-BB 
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ERK 2 Phosphorylation: 
 
 
Figure 3.8.4: Western Blot of ERK 2 phosphorylation at 42 kDa stimulated with LPA and 
PDGF-BB 
The bands were quantified using the software Genetools (figures 3.8.5/6). 
ERK 2 phosphorylation is not increased by the combination of LPA with PDGF-BB. The 
same pattern is observed as for ERK 1.  
There are high levels of protein available for samples stimulated with LPA; however these 
illustrate very low levels of phosphorylation. In comparison there are very low levels of 
protein available for the sample stimulated with PDGF-BB ligand alone, and yet it has the 
highest level of phosphorylation. 
 This could conclude that PDGF receptor phosphorylation doesn’t activate ERK 2; however 
this could also be a major error due to the medium used. Therefore a repeat is crucial 
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Figure 3.8.5: Phosphorylation of ERK 2 in response to stimulation with LPA and PDGF-BB 
 
Figure 3.8.6: Total ERK 2 protein available in response to stimulation with LPA and PDGF-BB 
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4. Discussion 
 
4.1 fMLP potentiates PDGF-BB ligand ability to phosphorylate the PDGF 
receptors 
 
The bands observed on figure 3.1.1a, which were the total cell lysate samples stimulated with 
fMLP and PDGF-BB, clearly illustrated that there was a high level of background banding on 
both the p-Tyr and CTB immunoblots. In order to assess the extent of background banding, 
the bands were quantified using the software GeneTools, and a significant level was 
observed. This was a problem as there could not be a real change in phosphorylation 
observed due to the peak in the unstimulated sample. This was due to the fact that the total 
cell lysate contains many other proteins as this has not been specifically purified for the 
PDGF receptor. Therefore it is expected that there will be many other proteins present in the 
sample, and thus results in a high background banding. It is very important to eliminate the 
background banding, as this gives an inaccurate result and the phosphorylation cannot be 
observed correctly. 
Unfortunately the IP method with CTB antibody did not work (figure 3.2.1) as there was a 
problem with the protein A beads and the antibody itself. An extensive period was spent 
attempting to precipitate the PDGF receptor out, however these were all futile and had no 
success.  Therefore WGA beads were used, which contains lectin, this binds all glycosylated 
proteins within the sample e.g. PDGF receptor (Piercenet., 2012).  However the problem with 
this method was that it still required an extensive amount of optimization as the bands 
observed on figure 3.2.2 are not clean and clear in comparison to those observed on the total 
cell lysate immunoblots. Again with the use of WGA beads, glycosylated proteins are bound; 
this could bind other proteins and therefore result in slightly higher levels of phosphorylation 
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observed.  It would have been more appropriate to have used the IP method which employed 
the C terminal antibody which would have directly bound to the PDGF β receptor.  
Although the method employing the WGA beads still required some optimization, the results 
observed on the western blot figure 3.2.2 were quantified using the software GeneTools, and 
the data obtained was very good. The background banding in the unstimulated sample had 
been reduced significantly on both the immunoblots (figures 3.2.3/4). When analysing the 
data from the p-Tyr blot, it was very clear that PDGF tyrosine phosphorylation was enhanced 
significantly in the samples stimulated with the combination of 5 ng/ml PDGF-BB ligand and 
100 nM fMLP. The second highest phosphorylation observed was in the samples stimulated 
with fMLP alone and then finally PDGF-BB stimulation alone. The same results were 
observed on the CTB immunoblots.  This data suggests that even in the absence of PDGF-BB 
ligand stimulation, fMLP is still capable of activating and phosphorylating the PDGF 
receptors. Therefore this would implicate that fMLP is directly activating PKC since recent 
studies have shown it to be a crucial point of activation as it promotes receptor recycling from 
early endosomes (Hellberg et al., 2009; Karlsson et al., 2006). 
In order to further investigate this new finding, the phosphorylation of MARCKS was 
monitored in response to stimulation with fMLP and PDGF-BB ligand. Myristoylated 
alanine-rich C-kinase substrate also known as MARCKS, is encoded for by the MARCKS 
gene and is regulated by PKC. Therefore the higher levels of activated PKC, the higher levels 
of phosphorylated MARCKS. 
The western blot on figure 3.3.1a clearly illustrated the increase in MARCKS 
phosphorylation in the samples which were stimulated with fMLP, in comparison to 
stimulation with PDGF-BB ligand alone.  Once this was quantified the data was much more 
easily to analyse and the highest peaks of phosphorylation are observed for the samples 
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stimulated with the combination and with fMLP alone. The phosphorylation reaches a peak at 
20-40 minutes where it then gradually begins to decrease. The levels of MARCKS 
phosphorylation observed for the samples stimulated with PDGF-BB ligand alone have very 
low levels. The MARCKS protein available corresponds with the phosphorylation observed 
(low levels of protein in sample stimulated with PDGF-BB alone etc).  Furthermore, after a 
peak is reached in all the three different stimulations, the level of phosphorylation decreases. 
This is due to Protein tyrosine phosphatases as recent research has identified that this family 
of enzymes regulate dephosphorylation via the removal of phosphate groups from the 
phosphorylated proteins (figure 1.6.1a). The loss of this enzyme results in the 
hyperphosphorylation of the PDGF receptor which leads to the formation of tumours as cell 
growth and differentiation is uncontrolled (Hellberg et al., 2009; Karlsson et al., 2006; 
Fischer et al., 1991). Therefore since the cells used were wild type, a period of 
phosphorylation followed by dephosphorylation was expected. Finally, MARCKS 
phosphorylation is significantly increased with the combination of fMLP with PDGF-BB and 
thus confirms the activation of PKC. 
An important aspect to consider is that scientifically it is required to clearly show that the 
phosphorylation observed really is what it is perceived to be and that receptor recycling is 
occuring.  Therefore to complete this data set initially PDGF receptor recycling and 
phosphorylation must be confirmed by using confocal analysis to analyse the PDGF β 
receptor sub-cellular localization. In addition to confirm that the receptor recycling is Rab4a 
dependant, by transfecting the cells with Rab4 dominant which inhibits Rab4a. An inhibitory 
effect of receptor phosphorylation would confirm that recycling is due to Rab4a. 
Finally there are no error bars displayed on the figures, as more time was required to repeat 
each experiment in addition to obtaining good results (due to optimization and duration of 
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experiments). Therefore these experiments should be repeated in order to show that the 
results are reproducible. 
4.2 fMLP potentiates downstream effector molecule AKT phosphorylation 
 
The phosphorylation of the downstream effector molecule AKT was investigated.  Protein 
kinase B also known as AKT is a protein kinase which can be either serine or threonine 
specific. In this project a serine 473 specific AKT was employed.  The AKT protein is 
activated and thus phosphorylated by PIP3 second messenger. The PI3 K generates 
phospholipids PIP3 second messenger which binds AKT and phosphorylates it. AKT plays 
key roles within the cell as it stimulates cell growth and prevents apoptosis resulting in cell 
survival. This has been implicated in many cancers (Majewski et al., 2004). 
From the western blot figure 3.3.2a, the results are quite difficult to determine, with a slight 
indication that the combination stimulation results in the highest level of AKT 
phosphorylation. Therefore the bands observed were quantified using GeneTools and the 
graphs analysed. From figure 3.3.2b (AKT phosphorylation), the samples stimulated with 
PDGF-BB alone and those with the combination have a peak at 10 minutes. Subsequently, 
the phosphorylation of samples stimulated with PDGF-BB alone decreases almost 
immediately at 10 minutes and continuous to do so. However up until 20 minutes, samples 
stimulated with fMLP continue to rise in phosphorylation and then gradually 
dephosphorylate. 
This was then compared to the total levels of AKT protein available, which corresponded 
with the results. There were higher levels of protein available for fMLP stimulation in 
comparison to PDGF-BB alone. 
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Therefore it can be assume that AKT phosphorylation is potentiated when fMLP is combined 
with PDGF-BB as fMLP activates PKC. A possible mechanism is that once PKC is activated 
the PDGF receptor is recycled which results in PDGF receptor phosphorylation. In addition 
this will then activate and phosphorylate PI3 K which leads to the phosphorylation and 
activation of AKT via PIP3 second messenger and thus AKT phosphorylation (Hellberg et 
al., 2009; Karlsson et al., 2006; Fischer et al., 1991). 
As mentioned beforehand there are no error bars displayed on the figures, as more time was 
required. Therefore these experiments should be repeated in order to show that the results are 
reproducible 
4.3 LPA stimulated PDGF receptor phosphorylation 
 
Previous studies have already established that LPA potentiates the ability of PDGF-BB ligand 
to phosphorylate the PDGF receptor and that this is due to receptor recycling as well as the 
activation of PKC. However before the findings on LPA were expanded, these experiments 
were repeated in order to obtain the same preliminary data and then continue on to investigate 
other downstream effector molecules as a control. 
The control experiment illustrated on the western blot on figure 3.4.1 was quantified and the 
graph (figure 3.4.2) illustrated that LPA does potentiate PDGF receptor phosphorylation. 
However this experiment was only stimulated for a period of 5 minutes and thus the kinetics 
for LPA with PDGF-BB was not established yet.  Unfortunately from this point onwards, the 
medium used for stimulation contained 5 % fetal bovine serum. This means the stimulation 
medium contained growth factors and thus could affect the results by means of increasing the 
levels of phosphorylation recorded, or causes inaccurate fluctuations in the phosphorylation 
curve. Nonetheless the results were analysed, as it was already expected for LPA to potentiate 
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PDGF receptor and MARCKS phosphorylation. Therefore if this is the same then it can be 
assumed that the use of the wrong medium did not have such devastating effects on the 
results.  However this data should be repeated using the correct medium. 
The kinetics for LPA combined with PDGF-BB ligand stimulations were conducted for its 
affect on PDGF receptor phosphorylation. The data is illustrated on the western blot figure 
3.5.1, which was the total cell lysate sample immunoblotted with CTB and p-Tyr antibodies, 
showed that there was a significant level of background banding in the unstimulated samples.  
Unfortunately the WGA beads did not work for this stimulation as this method still requires 
extensive optimization, and as previously mentioned the IP method was not functioning. 
Therefore, the peaks for the unstimulated samples were disregarded and the other time points 
were assessed.  On the p-Tyr immunoblots (figure 3.5.2) illustrating the total tyrosine 
phosphorylation of the PDGF receptor, the data was positive that the combination of LPA 
with PDGF-BB ligand increases phosphorylation. This is followed by LPA stimulation alone 
and finally the lowest phosphorylation was observed for stimulation with PDGF-BB alone. 
The same result was observed on the CTB immunoblots (figure 3.5.3). 
Since the data obtained is what has been previously established and also expected for this 
experiment, it is assumed that the medium did not have a significant effect.  Therefore the 
next step was to confirm that MARCKS phosphorylation is proportionately. 
The western blot on figure 3.4.6 and the quantification on figures 3.4.7/8, for the 
phosphorylation of MARCKS and the total MARCKS protein available confirmed previous 
findings that it is activated in response to combination of LPA with PDGF-BB. The increase 
in phosphorylation occurs after 20 minutes, where it continues to increase and remain high 
even after 60 minutes. Therefore the increase noted in MARCKS phosphorylation after 
combining LPA with PDGF-BB ligand requires a period of time, but it does activate 
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MARCKS. At this point the downstream effector molecules AKT and ERK1/2 
phosphorylation was investigated.  
It was observed on the western blot figures and quantifications for AKT that there was no 
increase in phosphorylation. In fact very high phosphorylation levels were observed for the 
sample stimulated with PDGF-BB ligand alone. This raises suspicion that perhaps due to the 
growth factors in the stimulation medium, very high levels were observed. In addition the 
phosphorylation levels observed for LPA were not low either; therefore this is most likely the 
cause for the results observed. 
Finally ERK 1 and ERK 2 are a chain of proteins activating the MAP kinase pathway within 
the cell and eventually resulting in the activation of transcription. As with AKT the same 
results were observed, where there is an abnormal high level of phosphorylation in the 
sample stimulated with PDGF-BB ligand alone leading to the conclusion that although the 
wrong medium did not affect the PDGF receptor and MARCKS phosphorylation; it did affect 
the downstream signalling molecules and their response to the stimulations. 
4.4 Conclusion & future research 
 
The first conclusions which can be derived from this project is that the previously un-
investigates cytokine fMLP has been shown to significantly potentiate the ability of PDGF-
BB ligand to phosphorylate the PDGF receptor. In addition this increase in phosphorylation 
also occurs in the absence of PDGF-BB, strongly suggesting that PKC is directly activated. 
Finally all downstream effector molecules of the PDGF receptor including MARCKS and 
AKT both have enhanced levels of phosphorylations when stimulated with fMLP. However 
this must be repeated several times to ensure the results are reproducible and that a confocal 
analysis of PDGF receptor localization is conducted to confirm receptor recycling. Finally the 
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cells should be transfected with Rab4 dominant which will inhibit the important Rab4a, and 
therefore assess whether the receptor recycling is dependent on this factor. 
The second conclusion is that the previous findings on LPA’s ability to increase PDGF 
receptor phosphorylation and activate protein kinase have been re-confirmed. However the 
downstream effector molecules were affected by the wrong medium which was used and thus 
this does require repetition to expand on the findings of LPA. 
Moving on, due to the important findings on fMLP, the hypothesis that PKC is a point of 
signal integration for PDGF receptor recycling is supported and is now a crucial point which 
must be investigated. This should be done by repeating the experiments on fMLP and also 
employing other G protein coupled cytokines, assessing whether these also result in PDGF 
receptor recycling. It is though that this will be found and that MARCKS will also be 
activated. Therefore if all cytokines result in the recycling of PDGF receptor, then they all 
must activate PKC and this then must be a point of signal integration for receptor recycling.  
If it found that PKC is indeed a point of signal integration it will be a major breakthrough as 
PKC is also a major and crucial point of activation for receptor recycling (Hellberg et al, 
2009).  Therefore this can then be targeted for novel anti cancer treatment and therapies. 
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